=> d l4 que stat;fil medl,biosis,embase,caplus;s l4
L1 STR



VAR G1=33/34
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L2 STR



VAR G1=33/34
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

7-1-2005

STEREO ATTRIBUTES: NONE
L4 27919 SEA FILE=REGISTRY SSS FUL L1 OR L2

100.0% PROCESSED 138317 ITERATIONS 27919 ANSWERS
SEARCH TIME: 00.00.02

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	248.08	248.29

FILE 'MEDLINE' ENTERED AT 11:08:10 ON 24 JUN 2005

FILE 'BIOSIS' ENTERED AT 11:08:10 ON 24 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:08:10 ON 24 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:08:10 ON 24 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

TOO MANY TERMS FOR FILE CROSSOVER IN L4
There are limits on the size of an answer set being crossed over from one file to another. Enter HELP CROSSOVER at an arrow prompt (=>) for specific information.

=> fil caplus;s l4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.00	251.29

FILE 'CAPLUS' ENTERED AT 11:08:17 ON 24 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2005 VOL 143 ISS 1
FILE LAST UPDATED: 23 Jun 2005 (20050623/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

L5 9232 L4

=> s l5 and (rhenium or nsc 600662 or re/mf or 7440-15-5 or technetium or tc/mf or 7440-26-8 or masurium)
REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L7 3930 L6

REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L9 14192 L8

REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L11 17078 L10

REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L13 19984 L12

33308 RHENIUM
8 RHENIUMS
33308 RHENIUM
(RHENIUM OR RHENIUMS)
3453 NSC
267 NSCS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

```
          3613 NSC
                 (NSC OR NSCS)
             0 600662
             0 NSC 600662
                 (NSC(W)600662)
         16512 TECHNETIUM
             1 TECHNETIUMS
         16512 TECHNETIUM
                 (TECHNETIUM OR TECHNETIUMS)
            58 MASURIUM
L14          145 L5 AND (RHENIUM OR NSC 600662 OR L13 OR L11 OR TECHNETIUM OR L9
                 OR L7 OR MASURIUM)


=> s l14 range=(,2000)
         26963 RHENIUM
             8 RHENIUMS
         26963 RHENIUM
                 (RHENIUM OR RHENIUMS)
          2699 NSC
            40 NSCS
          2730 NSC
                 (NSC OR NSCS)
             0 600662
             0 NSC 600662
                 (NSC(W)600662)
         13462 TECHNETIUM
             1 TECHNETIUMS
         13462 TECHNETIUM
                 (TECHNETIUM OR TECHNETIUMS)
            55 MASURIUM
L15          58 L5 AND (RHENIUM OR NSC 600662 OR L13 OR L11 OR TECHNETIUM OR L9
                 OR L7 OR MASURIUM)

=> s sharma s?/au
L16        6389 SHARMA S?/AU

=> s l15 not l16
L17          57 L15 NOT L16

=> d ibib abs
```

L17 ANSWER 1 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:572988 CAPLUS
DOCUMENT NUMBER: 133:275535
TITLE: Syntheses and structures of technetium(V) and rhenium(V) oxo complexes of peptide having KYC-sequence
AUTHOR(S): Takayama, Tsutomu; Suzuki, Keisuke; Sekine, Tsutomu; Kudo, Hiroshi
CORPORATE SOURCE: Department of Chemistry, Graduate School of Science, Tohoku University, Sendai, 980-8578, Japan
SOURCE: Radiochimica Acta (2000), 88(3-4), 247-251
CODEN: RAACAP; ISSN: 0033-8230
PUBLISHER: R. Oldenbourg Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Tc(V) and Re(V) oxo complexes of a peptide having a KYC-sequence such as KYCAR (H3L5) and KYCAREPPTRTNAYWGQG-NH2 (H3L18) were synthesized, and structures of the complexes were characterized by spectroscopic techniques. All of the complexes were synthesized by the ligand exchange reaction of (Bu4N)[MOCl4] (M = 99Tc, Re) with peptide in MeOH or DMF solution
These complexes have a square pyramidal structure with an oxo ligand at the apical position. The peptide is coordinated to a metal atom through Namine of lysine, Sthiol of cysteine, and Namide of tyrosine and cysteine in the equatorial plane. A lysine (CH2)4NH2 group of the L5 ligand has the syn conformation with respect to metal-oxo bonding in the complex. The syn isomer was selectively formed in the ligand exchange reaction. The conversion of the syn isomer to the anti isomer was observed only for syn-[ReO(L5)], in which the coordination of H2O to the trans position of the oxo ligand was involved.
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 2-57 ibib abs

L17 ANSWER 2 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:464011 CAPLUS
DOCUMENT NUMBER: 133:105344
TITLE: Preparation of technetium-99m labeled peptides for imaging
INVENTOR(S): Dean, Richard T.; Buttram, Scott; Mcbride, William; Lister-James, John; Civitello, Edgar R.
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 871,282.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6086849	A	20000711	US 1995-170299	19950209
US 5965107	A	19991012	US 1992-871282	19920430
WO 9321962	A1	19931111	WO 1993-US3687	19930419
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1992-871282	A2 19920430
			WO 1993-US3687	W 19930419
			US 1992-851074	B2 19920313

OTHER SOURCE(S): MARPAT 133:105344
AB This invention relates to radiolabeled peptides and methods for producing such peptides. Thus, peptide BAT-RALVDTLKFVTQAEGAKamide [BAT = HSCMe2CH2NHCH2CH2N(CH2CMe2SH)CH2CH2CH2CH2CO] (P215) was prepared and radiolabeled with Tc-99m and used for localization and in vivo imaging of atherosclerotic plaque in the hypercholesterol rabbit model.
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 3 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:454201 CAPLUS
DOCUMENT NUMBER: 133:70819
TITLE: Thrombus imaging agents
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 27 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6083481	A	20000704	US 1998-141127	19980827
PRIORITY APPLN. INFO.:			US 1998-141127	19980827

AB This invention relates to radiolabeled reagents that are scintigraphic imaging agents for imaging sites of thrombus formation in vivo, and methods for producing such reagents. Specifically, the invention relates to reagents each comprised of a specific binding compound, capable of binding to at least one component of a thrombus, covalently linked to a radiolabel-binding moiety. The invention provides these reagents, methods and kits for making such reagents, and methods for using such reagents labeled with technetium-99m to image thrombus sites in a mammalian body.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 4 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:307076 CAPLUS
DOCUMENT NUMBER: 132:339324
TITLE: Compositions that specifically bind to colorectal cancer cells and methods of using the same
INVENTOR(S): Waldman, Scott A.
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: U.S., 48 pp., Cont.-in-part of U.S. 5,518,888.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060037	A	20000509	US 1996-635930	19960426
US 5518888	A	19960521	US 1993-141892	19931026
US 5601990	A	19970211	US 1994-305056	19940913
WO 9511694	A1	19950504	WO 1994-US12232	19941026
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5731159	A	19980324	US 1997-789270	19970128
US 5928873	A	19990727	US 1998-46178	19980323
US 6268159	B1	20010731	US 1998-138237	19980821
US 6455251	B1	20020924	US 1999-304193	19990503
US 2003068641	A1	20030410	US 2002-253321	20020924
PRIORITY APPLN. INFO.:			US 1993-141892	A2 19931026
			US 1994-305056	A2 19940913
			WO 1994-US12232	W 19941026
			US 1995-468449	A3 19950606
			US 1997-789270	A1 19970128
			US 1998-46178	A1 19980323
			US 1999-304193	A3 19990503

AB Conjugated compds. which comprise an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compns. comprising a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer are disclosed. Methods of radioimaging metastasized colorectal cancer cells are disclosed. In vitro methods, kits and reagents are disclosed for determining whether or not an individual has metastasized colorectal cancer cells, for determining whether tumor cells are colorectal in origin and for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells.

L17 ANSWER 4 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 5 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:283942 CAPLUS
DOCUMENT NUMBER: 132:308663
TITLE: Preparation of technetium-99m labeled peptides for thrombus imaging
INVENTOR(S): Mcbride, William; Dean, Richard T.; Lister-james, John; Civitello, Edward R.
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 22 pp., Cont.-in-part of U.S. 5,645,815.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6056940	A	20000502	US 1996-535170		19960111
WO 9423758	A1	19941027	WO 1994-US3878		19940408
W: AU, CA, JP, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2363780	C	20030107	CA 1994-2363780		19940408
US 5645815	A	19970708	US 1995-439905		19950512
US 5997845	A	19991207	US 1997-902367		19970729
PRIORITY APPLN. INFO.:			US 1993-44825	B1	19930408
			WO 1994-US3878	W	19940408
			US 1995-439905	A2	19950512
			US 1991-653012	B2	19910208
			US 1992-886752	B1	19920521
			US 1992-893981	A3	19920605
			CA 1994-2160120	A3	19940408
			US 1994-273274	A2	19940711
			US 1995-462668	B1	19950605
			US 1995-469858	A	19950606

OTHER SOURCE(S): MARPAT 132:308663
AB This invention relates to radiolabeled scintigraphic imaging agents and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compds., including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compds., and methods for using such compds. labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body. Thus, N-[2-[bis(2-maleimidoethyl)amino]ethyl]-N6,N9-bis(2-methyl-2-triphenylmethylthiopropyl)-6,9-diazanonanamide (BAT-BM) was prepared and reacted with thiol-peptides in the synthesis of technetium -99m-labeled peptides.

L17 ANSWER 5 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 6 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:144782 CAPLUS
DOCUMENT NUMBER: 132:191387
TITLE: Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids
INVENTOR(S): Ziv, Ilan; Shirvan, Anat
PATENT ASSIGNEE(S): NST Neurosurvival Technologies Ltd., Israel
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010673	A1	20000302	WO 1999-IL459	19990823
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9953849	A1	20000314	AU 1999-53849	19990823
WO 2001018031	A2	20010315	WO 2000-IL459	20000801
WO 2001018031	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1226165	A2	20020731	EP 2000-948239	20000801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			IL 1998-125908	A 19980824
			US 1998-200715	A 19981127
			IL 1999-131266	A 19990805
			WO 1999-IL459	W 19990823
			WO 2000-IL459	W 20000801

AB Disclosed are an affinity filter and method of using same, effective in capturing and thereby removing particles characterized by surface exposure of anionic phospholipids present in a biol. fluid, particularly blood or blood-derived products. Examples of other biol. fluids include semen, cerebrospinal fluid, urine and mucous. The affinity filter includes a body formed with an inlet and an outlet, including a solid support and an anionic-phospholipid binding compound linked to the solid support. The

L17 ANSWER 6 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
charged anionic-phospholipid binding compd. serves for specifically binding the particles characterized by surface exposure of anionic phospholipids and thereby removing the particles from the biol. fluid, and particularly from blood or blood-derived products, for example in order to prep. the blood or blood-derived product for transfusion into a subject. Myristate-GGGKKKKKRFSFKKSFKLSGFSFKKNKKK(biotin) was prepd. on a peptide synthesizer and shown to bind to cells undergoing apoptosis.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 7 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:95998 CAPLUS
DOCUMENT NUMBER: 132:148551
TITLE: Radiolabeled compounds for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6022857	A	20000208	US 1998-100537	19980619
PRIORITY APPLN. INFO.:			US 1998-100537	19980619

AB This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compds., including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compds., and methods for using such compds. labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 8 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:64361 CAPLUS
DOCUMENT NUMBER: 132:344882
TITLE: 186Re-labelling of an endothelin derivative
AUTHOR(S): Noll, B.; Dinkelborg, L.; Hilger, H.
CORPORATE SOURCE: Schering AG, Germany
SOURCE: Wissenschaftlich-Technische Berichte - Forschungszentrum Rossendorf (1999), FZR-270, 188-189
CODEN: WBFRFQ; ISSN: 1437-322X
DOCUMENT TYPE: Report
LANGUAGE: German
AB Ligand exchange reaction between 186Re(V) gluconate and the peptide Asp-Gly-Gly-Cys-Gly-Cys-Phe-(D-Trp)-Leu-Asp-Ile-Ile-Trp results in a product that contains 2 species separable by HPLC. The complexes are stable for over 24 h and useful for in vivo animal studies.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 9 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:44678 CAPLUS
DOCUMENT NUMBER: 132:319290
TITLE: Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1
AUTHOR(S): Welling, Mick M.; Nibbering, Peter H.; Paulusma-Annema, Akke; Hiemstra, Pieter S.; Pauwels, Ernest K. J.; Calame, Wim
CORPORATE SOURCE: Department of Radiology, Leiden University Medical Center, Leiden, 2300 RC, Neth.
SOURCE: Journal of Nuclear Medicine (1999), 40(12), 2073-2080
CODEN: JNMEAQ; ISSN: 0161-5505
PUBLISHER: Society of Nuclear Medicine, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This study was undertaken to evaluate whether 99mTc-labeled human neutrophil peptide (HNP)-1 can be used as a tracer for rapid visualization of bacterial infections. Methods: Mice were injected i.m. with 1 million Staphylococcus aureus or Klebsiella pneumoniae organisms and 5 min later were injected i.v. with 0.4 μg (0.8 MBq) 99mTc-HNP-1. At various intervals, detailed information about clearance and accumulation of this tracer at sites of infection and in various organs was obtained by scintigraphy. 99mTc-labeled IgG (IgG), an established marker of infection and inflammation, was used for comparison. Results: After injection into S. aureus- or K. pneumoniae-injected mice, 99mTc-HNP-1 was rapidly removed from the circulation, mainly through the kidneys and bladder, with half-lives of 170 and 55 min, resp. Similar half-lives were observed for 99mTc-IgG in these animals. Visualization of foci with S. aureus or K. pneumoniae, as indicated by a ratio of 1.3 or higher between the targeted thigh muscle (containing bacteria) and the nontargeted (contralateral) thigh muscle (T/NT), was already achieved 5 min after injection of 99mTc-HNP-1. Similar T/NTs for 99mTc-IgG were obtained 4 h after injection of the tracer, indicating that imaging of foci of bacteria with 99mTc-HNP-1 is much faster than with 99mTc-IgG. To obtain insight into factors that contribute to accumulation of 99mTc-HNP-1 at sites of infection, the binding of this tracer to bacteria and leukocytes was assessed using a peritoneal infection model. Binding of 99mTc-HNP-1 to bacteria was approx. 1000 times higher than binding to leukocytes. Although the number of bacteria in the peritoneum was 1000-fold lower than the number of leukocytes, a significant correlation between binding of 99mTc-HNP-1 to bacteria on the one hand and accumulation of tracer on the other was still found, in contrast to 99mTc-IgG. Conclusion: 99mTc-HNP-1 allows rapid visualization of bacterial infections. Binding of this tracer to bacteria most likely contributes significantly to the accumulation of 99mTc-HNP-1 at sites of infection.
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 10 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:780311 CAPLUS
DOCUMENT NUMBER: 132:20545
TITLE: Technetium-99m labeled peptides for imaging
INVENTOR(S): Dean, Richard T.; Buttram, Scott; Mcbride, William; Lister-James, John; Civitello, Edgar R.
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 653,012, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5997844	A	19991207	US 1994-253678	19940603
US 6017509	A	20000125	US 1993-92355	19930715
US 5989519	A	19991123	US 1994-290853	19941011
CA 2191950	AA	19951214	CA 1995-2191950	19950601
CA 2191950	C	20030128		
WO 9533498	A1	19951214	WO 1995-US7017	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9527783	A1	19960104	AU 1995-27783	19950601
AU 697048	B2	19980924		
EP 762901	A1	19970319	EP 1995-922946	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1154072	A	19970709	CN 1995-194335	19950601
CN 1090973	B	20020918		
JP 10501241	T2	19980203	JP 1996-501223	19950601
ZA 9504547	A	19960124	ZA 1995-4547	19950602
US 5681541	A	19971028	US 1995-464456	19950605
US 5788960	A	19980804	US 1995-463052	19950605
US 6074627	A	20000613	US 1996-582134	19960514
US 5997845	A	19991207	US 1997-902367	19970729
PRIORITY APPLN. INFO.:			US 1991-653012	B2 19910208
			US 1993-92355	A2 19930715
			US 1991-807062	A2 19911127
			US 1992-851074	B2 19920313
			US 1992-886752	B1 19920521
			US 1992-893981	A3 19920605
			WO 1993-US2320	W 19930312
			US 1993-44825	B1 19930408
			US 1994-253678	A2 19940603
			US 1994-263758	A3 19940622
			US 1994-273274	A2 19940711

L17 ANSWER 10 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 1995-439905	A3	19950512
WO 1995-US7017	W	19950601
US 1995-462668	B1	19950605
US 1995-469858	A	19950606

OTHER SOURCE(S): MARPAT 132:20545

AB This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to peptides, methods and kits for making such peptides, and methods for using such peptides to image sites in a mammalian body labeled with **technetium**-99m (Tc-99m) via a radiolabel-binding moiety covalently attached to a specific binding peptide via an amino acid side-chain of the peptide.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:748161 CAPLUS
DOCUMENT NUMBER: 132:3554
TITLE: Preparation of **Technetium**-99m labeled peptides for imaging inflammation
INVENTOR(S): Dean, Richard T.; Lees, Robert S.; Buttram, Scott; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 851,074, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5989519	A	19991123	US 1994-290853	19941011
WO 9317719	A1	19930916	WO 1993-US2320	19930312
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5997844	A	19991207	US 1994-253678	19940603
US 5711931	A	19980127	US 1995-472535	19950607
US 5807538	A	19980915	US 1995-484774	19950607
PRIORITY APPLN. INFO.:			US 1992-851074	B2 19920313
			WO 1993-US2320	W 19930312
			US 1994-253678	A2 19940603
			US 1991-653012	B2 19910208
			US 1993-92355	A2 19930715
			US 1994-266178	A3 19940627

OTHER SOURCE(S): MARPAT 132:3554

AB This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to **technetium**-99m (Tc-99m) labeled leukocyte-binding peptides, methods and kits for making such peptides, and methods for using such peptides to image sites of infection and inflammation in a mammalian body. Thus, Ac-CAcmGCAcmGGG(VPGVG)4-amide (Acm = acetamidomethyl) was prepared by the solid-phase method and its Tc-99m labeled complex used for scintigraphic imaging and biodistribution in rabbits which were inoculated i.m. with a potent strain of E. Coli.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:655846 CAPLUS
DOCUMENT NUMBER: 131:272182
TITLE: Preparation of **technetium**-99m labeled peptides for imaging
INVENTOR(S): Dean, Richard T.; Buttram, Scott; McBride, William; Lister-James, John; Civitello, Edgar R.
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 851,074, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5965107	A	19991012	US 1992-871282	19920430
PT 630265	T	20030731	PT 1993-911556	19930312
ES 2194846	T3	20031201	ES 1993-911556	19930312
WO 9321962	A1	19931111	WO 1993-US3687	19930419
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9341076	A1	19931129	AU 1993-41076	19930419
AU 681080	B2	19970821		
EP 637968	A1	19950215	EP 1993-910660	19930419
EP 637968	B1	19990908		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
JP 07506111	T2	19950706	JP 1993-519337	19930419
AT 184203	E	19990915	AT 1993-910660	19930419
CA 2111863	C	20010424	CA 1993-2111863	19930419
US 6017510	A	20000125	US 1994-266178	19940627
US 6086849	A	20000711	US 1995-170299	19950209
US 5849261	A	19981215	US 1995-414424	19950331
US 5720934	A	19980224	US 1995-486135	19950606
US 5776428	A	19980707	US 1995-468975	19950606
US 5780007	A	19980714	US 1995-470152	19950606
US 5922303	A	19990713	US 1995-468964	19950606
US 6093383	A	20000725	US 1995-467791	19950606
US 5711931	A	19980127	US 1995-472535	19950607
US 5807538	A	19980915	US 1995-484774	19950607
AU 9724879	A1	19970904	AU 1997-24879	19970613
AU 717857	B2	20000406		
PRIORITY APPLN. INFO.:			US 1992-851074	B2 19920313
			US 1991-653012	B1 19910208
			US 1991-807062	A2 19911127
			US 1992-871282	A2 19920430
			WO 1993-US3687	A 19930419
			US 1994-236402	A 19940502
			US 1994-253973	A 19940603
			US 1994-264176	B2 19940622

L17 ANSWER 12 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 1994-266178	A3	19940627

OTHER SOURCE(S): MARPAT 131:272182

AB This invention relates to radiolabeled peptides and methods for producing such peptides. Thus, peptide BAT-RALVDTLKFVTQAEGAKamide [BAT = HSCMe2CH2NHCH2CH2N(CH2CMe2SH)CH2CH2CH2CH2CO] was prepared and radiolabeled with Tc-99m. Protected BAT was prepared from triphenylmethyl mercaptan, 2-bromo-2-methylpropanal, ethylenediamine, and Et 5-bromovalerate.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:511060 CAPLUS
DOCUMENT NUMBER: 131:155368
TITLE: Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
INVENTOR(S): Snow, Robert A.; Delecki, Daniel J.; Shah, Chandra; Black, Christopher; Wolfe, Henry
PATENT ASSIGNEE(S): Nycomed Imaging As, Norway; Matthews, Derek Peter
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9939748	A1	19990812	WO 1999-GB396	19990208
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9925301	A1	19990823	AU 1999-25301	19990208
PRIORITY APPLN. INFO.:			US 1998-20233 A	19980206
			WO 1999-GB396 W	19990208

OTHER SOURCE(S): MARPAT 131:155368
AB A targeting immunoreagent comprising a metal ion, a residue of a complexing agent and an immunoreactive group linked to said complexing agent having structure (I), wherein each R and R1 is independently selected from hydrogen, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyalkyloxy, alkoxyalkyloxy, alkylthio, alkylthioalkyl, alkylthioalkyloxy, hydroxyalkylthio, hydroxyalkylthioalkyl, hydroxyalkylthioalkyloxy, N,N--dialkylamino, N-(hydroxyalkyl)-N-alkylamino, N,N--bis(hydroyalkyl)amino, N,N-dialkylaminoalkyl, N--(hydroxyalkyl)-N-alkylaminoalkyl, N-N-bis(hydroxyalkyloaminoalkyl), alkylformamido, formamidoalkyl, aryl, alkylaryl, alkoxyaryl, hydroxyalkylaryl, alkoxyalkylaryl, hydroxyalkyloxyaryl, alkoxyalkyloxyaryl, alkylthioaryl, hydroxyalkylthioaryl, hydroxyalkylthioalkylaryl, hydroxyalkylthioalkyloxyaryl, aralkyl, aralkyloxy, alkoxyaralkyl, alkoxyaralkyloxy, aryloxy, alkylarylaxy, alkoxyaryloxy, and heterocyclyl; each Q is independently selected from hydrogen, alkyl, hydroxyl, carboxyl, carboxyalkyl, hydroxyalkyl, alkylthioalkyl, sulfhydryl, thioalkyl, alkoxy, alkylthio, alkylamino, aminoalkyl, aminoalkylaminoalkyl, hydroxy-alkylaminoalkyl, hydroxylaminoalkyl, hydroxamido, formamidoalkyl, alkylformamido, aryl, including substituted aryl, aryloxy, heterocyclyl, carbonyliminodiacetic acid, methyle eiminodiacetic acid, methylenethioethylene-iminodiacetic acid, carboxyalkylthioalkyl, a residue of ethylenediaminetetraascetic acid

L17 ANSWER 13 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(EDTA), a residue of diethylenetriaminepentaaceti. The immunoreagent comprises a ST receptor binding (targeting) moiety derived from e.g. Escherichia coli heat-labile enterotoxin. Since ST receptors occur naturally only in the intestine lumen and are found elsewhere in the body only as a result of metastasis of colon cancer, therefore, the disclosed immunoreagents are useful for diagnostic imaging and radiol. treatment of tumors.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 14 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:458425 CAPLUS
DOCUMENT NUMBER: 132:148528
TITLE: **Technetium**-99m somatostatin analogues: effect of labelling methods and peptide sequence
AUTHOR(S): Decristoforo, Clemens; Mather, Stephen J.
CORPORATE SOURCE: Nuclear Medicine Research Laboratory, St. Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK
SOURCE: European Journal of Nuclear Medicine (1999), 26(8), 869-876
CODEN: EJNMD9; ISSN: 0340-6997
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In this paper the preclin. evaluation of the somatostatin analog RC160 labeled with **technetium**-99m using bifunctional chelators (BFCs) based on the hydrazinonicotinamide (HYNIC) and N3S system is described and a comparison made with [Tyr3]-octreotide (TOC). Conjugates of both peptides with HYNIC, and of RC160 with benzoyl-MAG3 and an N3S-adipate derivative were prepared and radiolabelling performed at high specific activities using tricine, tricine/nicotinic acid and ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligands for HYNIC conjugates. All conjugates and 99mTc-labeled peptides showed preserved binding affinity for the somatostatin receptor (IC50, Kd<5 nM). The biodistribution was markedly dependent on the BFC and co-ligand used, with the amidothiol ligands showing a greater degree of hepatobiliary clearance, the HYNIC/tricine complex higher blood levels and the HYNIC/EDDA complex the highest level of renal excretion and lowest blood levels. All peptide conjugates showed receptor-mediated uptake in tumor xenografts, but tumor uptake was significantly lower for the 99mTc-RC160 derivs. compared with 99mTc-EDDA/HYNIC-[Tyr3]-octreotide (0.2%-3.5%ID/g vs 9.7%ID/g) and correlated well with the reduced internalization rate for RC160 derivs. Our results show that the selection of the labeling approach as well as the right choice of the peptide structure are crucial for labeling peptides with 99mTc to achieve complexes with favorable biodistribution. Despite the relatively low tumor uptake compared with 99mTc-EDDA/HYNIC-[Tyr3]-octreotide, 99mTc-RC160 could play a role in imaging tumors that do not bind octreotide derivs.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 15 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:450816 CAPLUS
DOCUMENT NUMBER: 131:113237
TITLE: **Technetium**-99m labeled peptides for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 43 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925331	A	19990720	US 1995-335832	19950105
WO 9323085	A1	19931125	WO 1993-US4794	19930521
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1004322	A2	20000531	EP 1999-124003	19930521
EP 1004322	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
US 5997845	A	19991207	US 1997-902367	19970729
JP 10291939	A2	19981104	JP 1998-45661	19980226
JP 3380738	B2	20030224		
PRIORITY APPLN. INFO.:			US 1992-886752 B2	19920521
			WO 1993-US4794 W	19930521
			US 1991-653012 B2	19910208
			US 1992-893981 A3	19920605
			US 1993-44825 B1	19930408
			EP 1993-914023 A3	19930521
			JP 1994-503844 A3	19930521
			US 1994-273274 A2	19940711
			US 1995-439905 A3	19950512
			US 1995-462668 B1	19950605
			US 1995-469858 A	19950606

AB Radiolabeled reagents are provided that are scintigraphic imaging agents for imaging sites of thrombus formation in vivo, as are methods for producing such reagents. Specifically, the invention relates to reagents each comprised of a specific binding compound, capable of binding to at least one component of a thrombus, covalently linked to a radiolabel-binding moiety. The invention provides these reagents, methods and kits for making such reagents, and methods for using such reagents labeled with **technetium**-99m to image thrombus sites in a mammalian body.
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS

L17 ANSWER 15 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 16 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:326492 CAPLUS
DOCUMENT NUMBER: 131:248216
TITLE: Labeling peptides with **rhenium-188**
AUTHOR(S): Melendez-Alafort, L.; Ferro-Flores, G.; Arteaga-Murphy, C.; Pedraza-Lopez, M.; Gonzalez-Zavala, M. A.; Tendilla, J. I.; Garcia-Salinas, L.
CORPORATE SOURCE: Instituto Nacional de Nutricion, Salvador Zubiran, Mex.
SOURCE: International Journal of Pharmaceutics (1999), 182(2), 165-172
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A direct labeling technique via EHDP for the preparation of 188Re-somatostatin analog peptide β-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-amide complex was developed. The influence of reaction conditions such as pH, temperature, weak ligand concentration and stannous chloride concentration were investigated. Methods of anal. were also established permitting identification of radiochem. impurities which may be present in the radiopharmaceutical solution Results showed that under the procedure reported herein 188Re-peptide complex can be prepared with a radiochem. purity of 90% and a specific activity up to 1.8 GBq mg-1 without radiolytic degradation of the product.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 17 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:219710 CAPLUS
DOCUMENT NUMBER: 130:264133
TITLE: **Technetium**-99m-labeled peptides for GPIIb/IIIa ligands useful for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 17 pp., Division of U.S. Ser. No. 273,274.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5888474	A	19990330	US 1995-478725	19950607
US 5443815	A	19950822	US 1991-807062	19911127
EP 1004322	A2	20000531	EP 1999-124003	19930521
EP 1004322	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
US 5849260	A	19981215	US 1994-273274	19940711
US 5681541	A	19971028	US 1995-464456	19950605
US 5788960	A	19980804	US 1995-463052	19950605
US 5811394	A	19980922	US 1995-480551	19950607
US 5968476	A	19991019	US 1995-484773	19950607
US 5997845	A	19991207	US 1997-902367	19970729
JP 10291939	A2	19981104	JP 1998-45661	19980226
JP 3380738	B2	20030224		
PRIORITY APPLN. INFO.:			US 1991-653012	B1 19910208
			US 1991-807062	A2 19911127
			US 1992-886752	B1 19920521
			US 1994-264176	B1 19940622
			US 1994-273274	A3 19940711
			US 1995-480551	A2 19950607
			US 1992-886052	B1 19920521
			US 1992-893981	A3 19920605
			US 1993-44825	B1 19930408
			EP 1993-914023	A3 19930521
			JP 1994-503844	A3 19930521
			US 1994-263758	A3 19940622
			US 1995-439905	A3 19950512
			US 1995-462668	B1 19950605
			US 1995-469858	A 19950606

AB Radiolabeled peptides, and methods for producing such peptides, are

L17 ANSWER 17 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
disclosed. Specifically, the invention relates to specific binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with **technetium**-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 18 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:194336 CAPLUS
DOCUMENT NUMBER: 130:232477
TITLE: Methods using NGR receptor binding for identifying molecules that home to angiogenic vasculature in tumors
INVENTOR(S): Ruoslahti, Erkki; Pasqualini, Renata
PATENT ASSIGNEE(S): The Burnham Institute, USA
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913329	A1	19990318	WO 1998-US18895	19980908
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6576239	B1	20030610	US 1997-926914	19970910
US 6180084	B1	20010130	US 1998-139802	19980825
AU 9894773	A1	19990329	AU 1998-94773	19980908
EP 1015884	A1	20000705	EP 1998-948140	19980908
R: CH, DE, FR, GB, IT, LI				
JP 2001516055	T2	20010925	JP 2000-511062	19980908
US 6491894	B1	20021210	US 2000-659786	20000911
US 2003113320	A1	20030619	US 2002-264374	20021003
US 2004096441	A9	20040520		
US 2003152578	A1	20030814	US 2003-375992	20030227
US 2004131623	A9	20040708		

PRIORITY APPLN. INFO.:

US 1997-926914	A	19970910
US 1998-139802	A	19980825
US 1996-60947P	P	19960910
US 1996-710067	A	19960910
WO 1998-US18895	W	19980908
US 2000-659786	A3	20000911

AB A method is disclosed for identifying a tumor homing mol. that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more mols. and determining specific binding of a mol. to the NGR receptor, where the presence of specific binding identifies the mol. as a tumor homing mol. that homes to angiogenic vasculature. The invention also provides a method of directing a moiety to angiogenic vasculature in a subject by administering to the subject a conjugate including a moiety linked to a tumor homing mol. that exhibits specific binding to an NGR receptor, whereby the moiety is directed to angiogenic vasculature. In addition, the invention provides a method of imaging the angiogenic vasculature of a tumor in a subject by administering to the subject a conjugate having a detectable moiety linked to a tumor homing mol. that exhibits specific binding to an NGR receptor and detecting the conjugate.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 19 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:181610 CAPLUS
DOCUMENT NUMBER: 130:219926
TITLE: Methods of treating metastatic colorectal cancer with heat-stable toxin (ST) receptor-binding compounds
INVENTOR(S): Waldman, Scott A.
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: U.S., 44 pp., Cont.-in-part of U.S. 5,518,888.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5879656	A	19990309	US 1996-583447	19960105
US 5518888	A	19960521	US 1993-141892	19931026
US 6268159	B1	20010731	US 1998-138237	19980821
US 2004029182	A1	20040212	US 2003-621684	20030717

PRIORITY APPLN. INFO.:

US 1993-141892	A2	19931026
US 1995-468449	A3	19950606
US 1996-583447	A1	19960105
US 1999-263477	B1	19990305

AB Conjugated compds. which comprise an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compns. comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor-binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST (heat-stable toxin of E. coli etc.) receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed. Methods of radioimaging metastasized colorectal cancer cells comprising the steps of first administering to an individual suspected of having metastasized colorectal cancer cells, a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent, and conjugated compound that comprises an ST receptor-binding moiety and a radioactive active moiety wherein the conjugated compound is present in an amount effective for diagnostic use in humans suffering from colorectal cancer and then detecting the localization and accumulation of radioactivity in the individual's body are disclosed.
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 20 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:175578 CAPLUS
DOCUMENT NUMBER: 130:219925
TITLE: Technetium-99m-labeled peptides for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 20 pp., Cont.-in-part of U.S. 5,443,815. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5879658	A	19990309	US 1995-475041	19950607
US 5443815	A	19950822	US 1991-807062	19911127
EP 1004322	A2	20000531	EP 1999-124003	19930521
EP 1004322	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
US 5849260	A	19981215	US 1994-273274	19940711
US 5681541	A	19971028	US 1995-464456	19950605
US 5788960	A	19980804	US 1995-463052	19950605
US 5811394	A	19980922	US 1995-480551	19950607
US 5968476	A	19991019	US 1995-484773	19950607
US 5997845	A	19991207	US 1997-902367	19970729
JP 10291939	A2	19981104	JP 1998-45661	19980226
JP 3380738	B2	20030224		
PRIORITY APPLN. INFO.:			US 1991-653012	B1 19910208
			US 1991-807062	A2 19911127
			US 1992-886752	B1 19920521
			US 1994-264176	B1 19940622
			US 1994-273274	A3 19940711
			US 1995-480551	A2 19950607
			US 1992-886052	B1 19920521
			US 1992-893981	A3 19920605
			US 1993-44825	B1 19930408
			EP 1993-914023	A3 19930521
			JP 1994-503844	A3 19930521
			US 1994-263758	A3 19940622
			US 1995-439905	A3 19950512
			US 1995-462668	B1 19950605

L17 ANSWER 20 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 1995-469858 A 19950606

OTHER SOURCE(S): MARPAT 130:219925
AB Radiolabeled peptides and methods for producing such peptides are provided. Specifically, the invention relates to specific-binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with technetium-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 21 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:123805 CAPLUS
DOCUMENT NUMBER: 130:293343
TITLE: Imaging thromboembolism with Tc-99m-labeled thrombospondin receptor analogs TP-1201 and TP-1300
AUTHOR(S): Pallela, V. R.; Thakur, M. L.; Consigny, P. M.; Rao, P. S.; Vasileva-Belnikolavska, D.; Shi, R.
CORPORATE SOURCE: Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, PA, 19107, USA
SOURCE: Thrombosis Research (1999), 93(4), 191-202 CODEN: THBRAA; ISSN: 0049-3848
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Two analogs derived from peptide CSVTCG that exists naturally in the mol. domain of the endogenous protein, thrombospondin, were labeled with 99mTc.
Binding of the peptides to activated and resting platelets, and to forming and preformed clots was evaluated. Tissue distribution studies in rabbits indicated that for both agents the target organ was the kidney with renal excretion the primary route of elimination of radioactivity. Deep venous thrombosis and pulmonary embolism were detectable by scintigraphy and image quality was similar for both agents.
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 22 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:721606 CAPLUS
DOCUMENT NUMBER: 130:7446
TITLE: Stents with a radioactive surface coating, their production and use for restenosis prevention
INVENTOR(S): Dinkelborg, Ludger; Blume, Friedhelm; Hilger, Christoph-Stephan; Heldmann, Dieter; Platzek, Johannes; Niedballa, Ulrich; Miklautz, Heribert; Speck, Ulrich; Duda, Stephan; Tepe, Gunnar; Noll, Bernhard; Goerner, Heidemarie
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: PCT Int. Appl., 42 pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9848851	A2	19981105	WO 1998-EP2527	19980429
WO 9848851	A3	19990422		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19724230	C1	19981126	DE 1997-19724230	19970603
DE 19724223	C1	19981224	DE 1997-19724223	19970603
DE 19724229	C1	19990401	DE 1997-19724229	19970603
AU 9879100	A1	19981124	AU 1998-79100	19980429
AU 739507	B2	20011011		
EP 979108	A2	20000216	EP 1998-929272	19980429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001522281	T2	20011113	JP 1998-546607	19980429
NZ 500584	A	20011130	NZ 1998-500584	19980429
CN 1109559	B	20030528	CN 1998-804684	19980429
MX 9909919	A	20000731	MX 1999-9919	19991028
NO 9905310	A	19991029	NO 1999-5310	19991029
NO 312817	B1	20020708		
US 6709693	B1	20040323	US 2000-627321	20000727
PRIORITY APPLN. INFO.:			DE 1997-19718340	A 19970430
			DE 1997-19718341	A 19970430
			DE 1997-19718342	A 19970430
			DE 1997-19724223	A 19970603
			DE 1997-19724229	A 19970603
			DE 1997-19724230	A 19970603
			WO 1998-EP2527	W 19980429

AB The surface of a metallic stent is coated with a radioactive metal isotope by chemical deposition (reduction or precipitation) or electrodeposition, or by chelation

L17 ANSWER 22 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
with a compd. which adheres to the stent (e.g. a peptide or lipid). Alternatively, the stent may be coated electrochem. with Au and then with a SH group-contg. chelate of a radioactive metal, where the SH group-contg. complexing agent adheres to the Au coating. Thus, a Wiktor stent was immersed in 1 mL EtOH soln. of 1-[3-[N-(2-methoxyethyl)octadecylsulfamoyl]-2-hydroxypropyl]-4,7,10-tris(hydroxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, 2 mL H2O was added, and the stent was sonicated for 15 min, removed, and dried. The coated stent was then immersed in 2 mL 0.9% NaCl soln., 37 MBq 111InCl3 was added, and the stent was sonicated for 15 min, rinsed in NaCl soln., and dried. The labeled stent had an activity of 1.49 MBq 111In.

L17 ANSWER 23 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:719130 CAPLUS
DOCUMENT NUMBER: 130:12050
TITLE: Platelet GPIIb/IIIa receptor-binding radiolabeled compounds for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John; Civitello, Edgar
R.; McBride, William
PATENT ASSIGNEE(S): Diatide Inc, USA
SOURCE: U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 44,325, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5830856	A	19981103	US 1994-253317	19940603
CA 2363780	C	20030107	CA 1994-2363780	19940408
CA 2191949	AA	19951214	CA 1995-2191949	19950601
WO 9533496	A1	19951214	WO 1995-US6909	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9527642	A1	19960104	AU 1995-27642	19950601
AU 709306	B2	19990826		
EP 772460	A1	19970514	EP 1995-940908	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1154071	A	19970709	CN 1995-194303	19950601
CN 1087630	B	20020717		
JP 10501236	T2	19980203	JP 1995-501180	19950601
ZA 9504549	A	19960226	ZA 1995-4549	19950602
US 5681541	A	19971028	US 1995-464456	19950605
US 5788960	A	19980804	US 1995-463052	19950605
US 6248304	B1	20010619	US 1996-721443	19960927
US 5997845	A	19991207	US 1997-902367	19970729
US 6022520	A	20000208	US 1998-100536	19980619
CN 1401661	A	20030312	CN 2002-122283	20020603

PRIORITY APPLN. INFO.: US 1991-653012 B2 19910208
US 1993-44825 B2 19930408
US 1992-886752 B2 19920521
US 1992-893981 A3 19920605
US 1994-210822 B2 19940318
CA 1994-2160120 A3 19940408
US 1994-253317 A 19940603
US 1994-263758 A3 19940622

L17 ANSWER 23 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 1994-273274	A2	19940711	
US 1995-439905	A1	19950512	
WO 1995-US6909	W	19950601	
US 1995-462668	B1	19950605	
US 1995-469858	A	19950606	

OTHER SOURCE(S): MARPAT 130:12050
AB Radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents, are provided. Specifically, the invention relates to specific binding compds., including peptides, that bind to the platelet GPIIb/IIIa receptor, methods and kits for making such compds., and methods for using such compds. labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 24 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:612212 CAPLUS
DOCUMENT NUMBER: 129:235643
TITLE: Isolation of tissue-specific peptide ligands and their use for targeting pharmaceuticals to organs
INVENTOR(S): Panet, Amos; Hagai, Yocheved; Lazarovits, Janette; Nimrod, Abraham; Vogel, Tikva; Levanon, Avigdor; Zeelon, Elisha; Belkind, Anna; Golan, Itshak
PATENT ASSIGNEE(S): Bio-Technology General Corp., USA
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839469	A1	19980911	WO 1998-US4188	19980304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2283474	AA	19980911	CA 1998-2283474	19980304
AU 9866825	A1	19980922	AU 1998-66825	19980304
EP 975792	A1	20000202	EP 1998-908909	19980304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ZA 9901669	A	20001016	ZA 1999-1669	19990302
WO 9945020	A1	19990910	WO 1999-US4691	19990304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9928012	A1	19990920	AU 1999-28012	19990304

PRIORITY APPLN. INFO.: US 1997-39509P P 19970304
US 1997-810074 A 19970304
WO 1998-US4188 W 19980304
US 1998-154404 A 19980910
WO 1999-US4691 W 19990304

AB The subject invention provides novel peptides and the use of these peptides in the treatment of various diseases and conditions. The novel peptides specifically bind to undetd. and determined targets in various organs and in lymphocytes. The subject invention also provides a method for the

L17 ANSWER 24 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
identification of a peptide by applying peptide library methodol. ex vivo to perfused organs.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 25 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:320246 CAPLUS
DOCUMENT NUMBER: 129:78567
TITLE: Structure-function correlation and biostability of antibody CDR-derived peptides as tumor imaging agents
AUTHOR(S): Hussain, Rohanah; Courtenay-Luck, Nigel S.; Siligardi, Giuliano
CORPORATE SOURCE: National Chiroptical Laboratory (EPSRC), Department of Chemistry, Birkbeck College, London, WC1H 0AJ, UK
SOURCE: Biomedical Peptides, Proteins & Nucleic Acids (1997), Volume Date 1996-1997, 2(3), 67-70
CODEN: BPPAFS; ISSN: 1353-8616
PUBLISHER: Mayflower Worldwide
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Based on the CDR3 VH sequence of a monoclonal antibody (ASM2) raised against human epithelial cancer cells, the synthetic peptide YCAREPPTRTFAYWG (EPPT1) has been found to have an appreciable affinity (Kd=20μM) for the deglycosylated mucin-derived peptide antigen YVTSAPDTRPAPGST (PDTRP). The technetium-radiolabeled form of this peptide has been found to be a good tumor-imaging candidate for diagnosis of breast carcinoma. Several EPPT1 peptide analogs were synthesized. A differential biostability was obtained blocking the end groups of EPPT1. The susceptibility to proteolytic degradation was significantly decreased for the C-amidated form of EPPT1 than the N-acetylated form. Using resonant mirror biosensor technique, the EPPT1 analogs were classified as active and non-active peptides according to their PDTRP-binding properties. The binding of EPPT1 to PDTRP in free solution was also determined unambiguously by CD spectroscopy. CD spectra of both active and non-active peptides showed the presence of irregular conformations in H2O and SDS above cmc. In TFE, significant degree of ordered conformations of α-helix or β-turn type were induced but did not correlate well with their binding properties. In SDS below cmc a conformational difference was observed between the active and non-active peptides. The active peptides exhibited CD spectra of aggregation of β-strand type while the non-active showed CD spectra similar to those in H2O and SDS above cmc, critical micelle concentration A good correlation between the extended conformation of β-strand type and the binding affinity of the active peptides suggests this conformation as the binding feature of the EPPT tumor-imaging peptides. These data are vital for the design of novel EPPT analogs. Any modification to improve binding affinity must retain the ability of the peptides to adopt the extended conformation of β-strand type.
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 26 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:214285 CAPLUS
DOCUMENT NUMBER: 128:292258
TITLE: Technetium-99m labeled peptides, and preparation thereof, for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 18 pp., Cont.-in-part of U.S. 5,443,815.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736122	A	19980407	US 1995-482880	19950607
US 5443815	A	19950822	US 1991-807062	19911127
US 5681541	A	19971028	US 1995-464456	19950605
US 5788960	A	19980804	US 1995-463052	19950605
US 5811394	A	19980922	US 1995-480551	19950607
US 5968476	A	19991019	US 1995-484773	19950607
US 5997845	A	19991207	US 1997-902367	19970729
PRIORITY APPLN. INFO.:			US 1991-653012	B1 19910208
			US 1991-807062	A2 19911127
			US 1992-886052	B1 19920521
			US 1994-264176	B1 19940622
			US 1995-480551	A2 19950607
			US 1992-886752	B1 19920521
			US 1992-893981	A3 19920605
			US 1993-44825	B1 19930408
			US 1994-263758	A3 19940622
			US 1994-273274	A3 19940711
			US 1995-439905	A3 19950512
			US 1995-462668	B1 19950605
			US 1995-469858	A 19950606

OTHER SOURCE(S): MARPAT 128:292258
AB Radiolabeled peptides, and methods for producing such peptides, are disclosed. Specifically, the invention relates to specific-binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with technetium-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.
REFERENCE COUNT: 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 26 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L17 ANSWER 27 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:214283 CAPLUS
DOCUMENT NUMBER: 128:280377
TITLE: Method for preparing radiolabeled peptides using protected polyaminocarboxylate ligands
INVENTOR(S): Srinivasan, Ananthachari
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736120	A	19980407	US 1996-660262	19960607

PRIORITY APPLN. INFO.: US 1996-660262 19960607

OTHER SOURCE(S): CASREACT 128:280377; MARPAT 128:280377
AB A method is provided for radiolabeling peptides using polyaminocarboxylate ligands having suitable protecting groups such that they can be added to peptides by standard solid phase or solution phase peptide synthetic chemical and can be deprotected using standard cleavage/deprotection reagents and produce the peptide/chelate conjugate as a high purity monoaddn. product is provided. The cleaved and deprotected ligand-peptide mols. can then be labeled with lanthanide or actinide radionuclides. The protected polyaminocarboxylate ligands form mono-anhydrides or mono-active esters under solid phase or solution phase conditions and permit only the desired monoaddn. chelate-peptide conjugate to be formed.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 28 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:190657 CAPLUS
DOCUMENT NUMBER: 128:289380
TITLE: A new type of mixed-ligand complexes of technetium(V) and rhenium(V) with mercaptoacetyl glycine (MAG1) and coligands containing reactive groups
AUTHOR(S): Noll, B.; Noll, S.; Jankowsky, R.; Spies, H.; Johannsen, B.
CORPORATE SOURCE: Institute Bioinorganic Radiopharmaceutical Chemistry, Research Center Rossendorf Inc., Dresden, D-01314, Germany
SOURCE: Forschungszentrum Rossendorf e.V., [Bericht] FZR (1997), FZR-200, 85-89
CODEN: FRBFEU
DOCUMENT TYPE: Report
LANGUAGE: English
AB Mercaptoacetylglycine as a tridentate ligand forms a variety of mixed-ligand Tc and Re complexes with various monodentate ligands functionalized with a free mercapto or isonitrile group. Several complexes were synthesized, selected compds. were analyzed by EXAFS spectroscopy. Biol. relevant mols. being used as the monodentated ligand can be labeled with Te or Re. To label biomols. with free carboxylic or amino groups, they can be coupled with preformed Tc/Re complexes. A labeling of mols. with halogen is based on the substitution of the halogen by a complex.

L17 ANSWER 29 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:749789 CAPLUS
DOCUMENT NUMBER: 128:83565
TITLE: Technetium coordination ability of cysteine-containing peptides: x-ray absorption spectroscopy of a 99Tc labeled endothelin derivative
AUTHOR(S): Johannsen, B.; Jankowsky, R.; Noll, B.; Spies, H.; Reich, T.; Nitsche, H.; Dinkelborg, L. M.; Hilger, C. S.; Semmler, W.
CORPORATE SOURCE: Forschungszentrum Rossendorf e. V., Institut fur Bioanorganische und Radiopharmazeutische Chemie, Dresden, D-01314, Germany
SOURCE: Applied Radiation and Isotopes (1997), 48(8), 1045-1050
CODEN: ARISEF; ISSN: 0969-8043
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The coordination mode of a 99Tc-labeled endothelin derivative, Asp-Gly-Gly-Cys-Gly-Cys-Phe-(D-Trp)-Leu-Asp-Ile-Ile-Trp, in solution was determined by x-ray absorption spectroscopy (XAS). XAS anal. revealed that coordination of the [TcO]3+ core is restricted to the sequence -Cys-Gly-Cys-. The preferred coordination by the cysteinyl thiol group prevents involvement of any donor atom other than S thus forming purely S-coordinate 1:2 complexes. Two occurring 99Tc complex species with identical coordination spheres were identified and seem likely to represent parallel and antiparallel peptide chain orientation isomers.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 30 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:340700 CAPLUS
DOCUMENT NUMBER: 126:305794
TITLE: Bifunctional sulfide-containing sulfonamides of type S2NY for chelation of radioactive isotopes
INVENTOR(S): Dinkelborg, Ludger; Hilger, Christoph Stephan; Kramp, Wolfgang; Platzek, Johannes; Raduechel, Bernd; Erber, Sebastian
PATENT ASSIGNEE(S): Institut fuer Diagnostikforschung Gmbh an der Freien Universitaet Berlin, Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19536785	A1	19970327	DE 1995-19536785	19950921
CA 2232315	AA	19970410	CA 1996-2232315	19960919
WO 9712636	A2	19970410	WO 1996-DE1825	19960919
W: AU, CA, HU, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9714361	A1	19970428	AU 1997-14361	19960919
EP 851770	A2	19980708	EP 1996-945141	19960919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: DE 1995-19536785 A 19950921
WO 1996-DE1825 W 19960919

OTHER SOURCE(S): MARPAT 126:305794
AB Complexes of radioisotopes of Tc or Re and ligands R1SCR2R3(CR4R5)nSCHR6CHR7SO2NH(R8R9)mCOB (R1 = H, alkyl, or protecting group; R2-R9 = H, alkyl; n, m = 1, 2; B = OH, SH, NH2 or substituted amino) were prepared for use in radiodiagnosis and radiotherapy. Thus, N-(5-mercapto-3-thiapentylsulfonyl)glycine was prepared from glycine Me ester by reaction with chloroethanesulfonyl chloride, mercaptoethanol, CCl4, and thiourea, followed by saponification The product was converted into the technetium-99m complex.

L17 ANSWER 31 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:340698 CAPLUS
DOCUMENT NUMBER: 126:305792
TITLE: Bifunctional sulfide-containing sulfonamides of type XSNY for chelation of radioactive isotopes
INVENTOR(S): Dinkelborg, Ludger; Hilger, Christoph Stephan; Kramp, Wolfgang; Platzek, Johannes; Raduechel, Bernd; Erber, Sebastian
PATENT ASSIGNEE(S): Institut fuer Diagnostikforschung Gmbh an der Freien Universitaet Berlin, Germany
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19536780	A1	19970327	DE 1995-19536780	19950921
CA 2232620	AA	19970410	CA 1996-2232620	19960919
WO 9712850	A2	19970410	WO 1996-DE1826	19960919
WO 9712850	A3	19970710		
W: AU, CA, HU, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9715399	A1	19970428	AU 1997-15399	19960919
EP 851847	A2	19980708	EP 1996-945341	19960919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: DE 1995-19536780 A 19950921
WO 1996-DE1826 W 19960919

OTHER SOURCE(S): MARPAT 126:305792
AB Complexes of radioisotopes of Tc or Re and liganda BCR1R2(CR3R4)nSCHR5CHR6SO2NHCR7R8(CR9R10)mD (R1-R10 = H, alkyl; R8 may also be CO2H or a carboxylic acid derivative; n, m = 1, 2; B, D = SH, OH, NH2 or their derivs.) were prepared for use in radiodiagnosis and radiotherapy. Thus, N-(5-amino-3-thiapentylsulfonyl)cysteine Me ester was prepared from S-(4-methoxybenzyl)cysteine Et ester by reaction with chloroethanesulfonyl chloride and N-Boc-2-mercaptoethylamine and removal of the protecting groups. The product was converted into the technetium-99m complex.

L17 ANSWER 32 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:276721 CAPLUS
DOCUMENT NUMBER: 126:343883
TITLE: Preparation and antitumor activity of radioactive peptide complexes
INVENTOR(S): McBride, William; Dean, Richard T.
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 902,935.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5620675	A	19970415	US 1993-95760	19930721
US 5716596	A	19980210	US 1992-902935	19920623
EP 1094074	A2	20010425	EP 2000-122243	19930623
EP 1094074	A3	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
ES 2164667	T3	20020301	ES 1993-918129	19930623
ZA 9307596	A	19940804	ZA 1993-7596	19931013
CA 2167678	AA	19950202	CA 1994-2167678	19940721
CA 2167678	C	20020702		
WO 9503330	A1	19950202	WO 1994-US8335	19940721
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9475506	A1	19950220	AU 1994-75506	19940721
AU 684823	B2	19980108		
ZA 9405367	A	19950405	ZA 1994-5367	19940721
JP 09501419	T2	19970210	JP 1995-505359	19940721
JP 3601827	B2	20041215		
EP 804481	A1	19971105	EP 1994-925686	19940721
EP 804481	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, IE				
AT 237637	E	20030515	AT 1994-925686	19940721
ES 2197169	T3	20040101	ES 1994-925686	19940721
US 5814298	A	19980929	US 1995-465764	19950606
US 5820845	A	19981013	US 1995-466100	19950606
US 5833942	A	19981110	US 1995-470932	19950606
US 5843401	A	19981201	US 1995-467025	19950606
AU 9877481	A1	19981001	AU 1998-77481	19980723

PRIORITY APPLN. INFO.: US 1992-902935 A2 19920623
EP 1993-918129 A3 19930623
US 1993-95760 A 19930721
WO 1994-US8335 W 19940721

OTHER SOURCE(S): MARPAT 126:343883
AB This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing label radiodiagnostic agents. Specifically, the invention relates to linear peptide derivs. and analogs of somatostatin, and embodiments of such

L17 ANSWER 32 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to linear peptide derivs. and analogs of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention so specifically relates to liner peptide derivs. and analogs of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 and rhenium-188 for use as radiotherapeutic agents. Methods and kits for making, radiolabeling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.

L17 ANSWER 33 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:253847 CAPLUS
DOCUMENT NUMBER: 126:235367
TITLE: Tumor-affinity peptide, and radioactive diagnostic and therapeutic agents containing the peptide
INVENTOR(S): Seki, Ikuya; Itaya, Yoshitoshi; Shirakami, Yoshifumi; Washino, Komei
PATENT ASSIGNEE(S): Nihon Medi-Physics Co. Ltd., Japan; Antisoma Limited
SOURCE: S. African, 62 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 9509206	A	19960104	ZA 1995-9206	19951031

PRIORITY APPLN. INFO.: ZA 1995-9206 19951031

OTHER SOURCE(S): MARPAT 126:235367
AB Peptides having an amino acid sequence containing 20 or less amino acid residues, the amino acid sequence being described as X1-YCAREPPT-X2 (A, C, E, P, R, T, Y = amino acid residues expressed by standard one-letter symbols, each of A, C, R and Y in amino acid sequence YCAR may be either L or D; X1 = basic organic compound having 1-3 amino groups; X2 = any given amino acid sequence), or salts thereof, are disclosed which have affinity with a tumor. Synthesis of peptides (sequences included) of the invention is described, as are e.g. biodistribution of 99mTc-labeled peptides and imaging of laryngeal cancer with a 99mTc-labeled peptide.

L17 ANSWER 34 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:194419 CAPLUS
DOCUMENT NUMBER: 126:248350
TITLE: Radiolabeled somatostatin analogs in prostate cancer
AUTHOR(S): Thakur, M. L.; Kolan, H.; Li, J.; Wiaderkiewicz, R.; Pallela, V. R.; Duggaraju, R.; Schally, A. V.
CORPORATE SOURCE: DEPARTMENT OF RADIOLOGY, THOMAS JEFFERSON UNIVERSITY HOSPITAL, PHILADELPHIA, PA, 19107, USA
SOURCE: Nuclear Medicine and Biology (1997), 24(1), 105-113
CODEN: NMBIEO; ISSN: 0883-2897
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compds. were evaluated in nude mice bearing exptl. human prostate cancers. In these studies, 111In-DTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-nonspecific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, ($p < 0.05$), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

L17 ANSWER 35 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:127463 CAPLUS
DOCUMENT NUMBER: 126:135593
TITLE: Radiolabeled peptide compositions for site-specific targeting
INVENTOR(S): Srinivasan, Ananthachari; Dyszlewski, Mary Marmion; Bugaj, Joseph E.
PATENT ASSIGNEE(S): Mallinckrodt Medical, Inc., USA
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640291	A1	19961219	WO 1996-US9384	19960606
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5830431	A	19981103	US 1995-480373	19950607
CA 2224153	AA	19961219	CA 1996-2224153	19960606
EP 831938	A1	19980401	EP 1996-922403	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 11507342	T2	19990629	JP 1996-501714	19960606
US 5804157	A	19980908	US 1997-989434	19971212
PRIORITY APPLN. INFO.:			US 1995-480373 A	19950607
			WO 1996-US9384 W	19960606

AB This invention relates to radiolabeled peptide compns. for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biol. site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.

L17 ANSWER 36 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:119199 CAPLUS
DOCUMENT NUMBER: 126:131780
TITLE: Preparation of radiometal-binding analogs of luteinizing hormone releasing hormone
INVENTOR(S): Mcbride, William J.; Karacay, Habibe; Griffiths, Gary L.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640756	A1	19961219	WO 1996-US8695	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5753206	A	19980519	US 1995-474555	19950607
CA 2223432	AA	19961219	CA 1996-2223432	19960607
AU 9661501	A1	19961230	AU 1996-61501	19960607
AU 712968	B2	19991118		
EP 836618	A1	19980422	EP 1996-919063	19960607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11513977	T2	19991130	JP 1996-501203	19960607
US 37710	E	20020521	US 2000-572339	20000518
PRIORITY APPLN. INFO.:			US 1995-474555 A	19950607
			WO 1996-US8695 W	19960607

OTHER SOURCE(S): MARPAT 126:131780

AB Peptide derivs. of LH-RH that are capable of binding radionuclides are provided. The peptide derivs. are readily labeled with isotopes of rhenium or technetium, while retaining their ability to tightly bind LH-RH receptors. Methods for preparing the labeled peptides and their use in methods of radiodiagnosis and radiotherapy are described. Thus, pGlu-His-Trp-Ser-Tyr-Lys(HSCH2CO-Gly-Cys)-Leu-Arg-Pro-Gly-NH2 was prepared by standard soldi-phase methods using 9-fluorenylmethoxycarbonyl (Fmoc) chemical and radiolabeled with Na99mTcO4 or Na188ReO4. Prepared radiolabeled LH-RH analogs were tested for receptor binding in vitro and also evaluated for biodistribution in mice.

L17 ANSWER 37 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:534401 CAPLUS
DOCUMENT NUMBER: 125:276563
TITLE: Synthesis of N-α-(6-hydrazinonicotinoyl)octreotide. A precursor of a [99mTc] complex
AUTHOR(S): Krois, Daniel; Riedel, Christina; Angelberger, Peter; Kalchhauser, Hermann; Virgolini, Irene; Lehner, Harald
CORPORATE SOURCE: Inst. Organische Chem., Univ. Wien, Vienna, A-1090, Austria
SOURCE: Liebigs Annalen (1996), (9), 1463-1469
CODEN: LANAEM; ISSN: 0947-3440
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of the title compound H-Hynic-D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-OH (I) via [3+4] and [7+2] segment condensation, resp., with minimal protection of amino acid side chains is presented. The need to include the 6-hydrazinonicotinic acid into a complete peptide synthesis originates from the poor regioselectivity of Boc2O towards the amino groups of octreotide (II) and from the distinct chemical properties of N-hydroxysuccinimidates of 6-hydrazinonicotinic acid derivs. in general. The structure of I, suitable for the preparation of a [99mTc]-labeled metal complex was established by spectroscopic methods. The study is complemented by conformational considerations on the pharmacophore of I and II based on CD and 2D-NMR.

L17 ANSWER 38 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:452351 CAPLUS
DOCUMENT NUMBER: 125:108361
TITLE: Metal chelate-forming peptides and use thereof for radiodiagnosis and radiotherapy
INVENTOR(S): Itaya, Yoshitoshi; Seki, Ikuya; Hanaoka, Koichi; Shirakami, Yoshifumi
PATENT ASSIGNEE(S): Nihon Medi-Physics Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 719790	A2	19960703	EP 1995-309302	19951220
EP 719790	A3	19970910		
EP 719790	B1	20030709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
CA 2165228	AA	19960628	CA 1995-2165228	19951214
JP 08231587	A2	19960910	JP 1995-347332	19951214
AU 9540495	A1	19960704	AU 1995-40495	19951218
AU 703230	B2	19990318		
ZA 9510850	A	19960625	ZA 1995-10850	19951220
US 5770178	A	19980623	US 1995-575863	19951220
AT 244726	E	20030715	AT 1995-309302	19951220
ES 2199974	T3	20040301	ES 1995-309302	19951220
TW 514641	B	20021221	TW 1995-84113708	19951221
BR 9506097	A	19971223	BR 1995-6097	19951227
US 5785948	A	19980728	US 1997-815530	19970312
PRIORITY APPLN. INFO.:			JP 1994-338024 A	19941227
			US 1995-575863 A3	19951220

AB The invention provides a metal chelate forming peptide having an amino acid sequence of three amino acid residues represented by: X1-X2-Cys, wherein X1 represents an amino acid residue other than Cys residue; X2 represents an amino acid residue other than Cys residue and Pro residue; functional groups at the N-terminus, C-terminus and side chain may be substituted with protecting groups; and each of the amino acid residues may be any of D-form and L-form. Further, the invention provides a complex of the peptide with a physiol. active peptide, protein or other substance; a labeled reagent obtained by labeling the peptide or the complex with a metal radionuclide; and a radiodiagnostic and radiotherapeutic composition comprising the metal radionuclide-labeled reagent.
Chelate-forming peptides conjugated to a tumor-targeting peptide or an inflammation-targeting peptide were synthesized. The stability of the chelates was determined Tc99-labeled conjugates were used for radioimaging of
tumors and inflammation in rats.

L17 ANSWER 39 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:214773 CAPLUS
DOCUMENT NUMBER: 124:261759
TITLE: Preparation of peptide chelates for diagnosis of vascular disease (atherosclerosis).
INVENTOR(S): Dinkelborg, Ludger; Hilger, Christoph Stephan; Semmler, Wolfhard; Speck, Ulrich; Henklein, Peter
PATENT ASSIGNEE(S): Institute Diagnostikforschung GmbH an der Freien Universitaet Berlin, Germany
SOURCE: Ger. Offen., 23 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4425778	A1	19960118	DE 1994-4425778	19940713
CA 2194294	AA	19960201	CA 1995-2194294	19950621
CA 2194294	C	20010731		
WO 9602568	A1	19960201	WO 1995-DE837	19950621
W: AU, CA, CN, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9527846	A1	19960216	AU 1995-27846	19950621
AU 698301	B2	19981029		
EP 772633	A1	19970514	EP 1995-923183	19950621
EP 772633	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1158621	A	19970903	CN 1995-194122	19950621
HU 77389	A2	19980428	HU 1997-70	19950621
JP 10506611	T2	19980630	JP 1996-504572	19950621
JP 3655312	B2	20050602		
AT 240352	E	20030515	AT 1995-923183	19950621
IL 114548	A1	20000831	IL 1995-114548	19950711
ZA 9505776	A	19960319	ZA 1995-5776	19950712
NO 9700109	A	19970311	NO 1997-109	19970110
US 6342201	B1	20020129	US 1997-765953	19970717
PRIORITY APPLN. INFO.:			DE 1994-4425778 A	19940713
			WO 1995-DE837 W	19950621

OTHER SOURCE(S): MARPAT 124:261759
AB Xz-Ly-(A1)a(A2)b-(A3)c-(A4)d-(A5)e-(A6)e-(A7)f-(A8)g-(A9)j-(A10)k-(A11)l-Ile-Ile-Trp-OH (a, b, c, d, e, f, g, h, j, k, l = 0-2; y, z = 0, 1; K = defined chelating group; A1-A11 = D- or L-amino acid residues), were prepared Thus, H-Cys-Phe-D-Trp-Leu-Asp-Ile-Ile-Trp-OH in DMF containing Et3N
was treated with thiodiglycolic acid anhydride to give 39.5% N-(4-hydroxycarboxy-1-oxo-3-thiabut-1-yl)-Cys-Phe-D-Trp-Leu-Asp-Ile-Ile-Trp-OH. The latter in rabbits showed an enrichment factor (plaque:nonplaque) of 14:1.

L17 ANSWER 40 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:184626 CAPLUS
DOCUMENT NUMBER: 124:229987
TITLE: Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
INVENTOR(S): Seki, Ikuya; Itaya, Yoshitoshi; Shirakami, Yoshifumi; Washino, Komei
PATENT ASSIGNEE(S): Nihon Medi-Physics Co., Ltd., Japan
SOURCE: Can. Pat. Appl., 52 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2151099	AA	19951208	CA 1995-2151099	19950606
JP 08053494	A2	19960227	JP 1995-158747	19950601
AU 9520499	A1	19951214	AU 1995-20499	19950605
AU 684348	B2	19971211		
US 5827498	A	19981027	US 1995-463230	19950605
EP 700930	A1	19960313	EP 1995-108681	19950606
EP 700930	B1	19991103		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
AT 186306	E	19991115	AT 1995-108681	19950606
ES 2138111	T3	20000101	ES 1995-108681	19950606
TW 394777	B	20000621	TW 1995-84112123	19951116
PRIORITY APPLN. INFO.:			JP 1994-148655 A	19940607

OTHER SOURCE(S): MARPAT 124:229987
AB A peptide having affinity with tumor or a salt thereof, which comprises an
amino acid sequence containing 20 or less amino acid residues, said amino acid
sequence being described as X1-YCAREPIT-X2 wherein A, C, E, P, R, T and Y represent amino acid residues expressed by standard one-letter symbols, each
of amino acid residues A, C, R and Y in the amino acid sequence YCAR may be in either L-form of D-form, X1 represents a basic organic compound having
1-3 amino groups, and X2 represents any given amino acid sequence, is provided together with a radioactive diagnostic agent and a radioactive therapeutic agent containing the above peptide or a salt thereof. The present
tumor affinity peptide is high in radioactive metal labeling yield, useful
for imaging and treating pathol. tissues such as of breast cancer, ovarian
cancer and colon cancer of mammals including human, and difficult to be readily metabolized in organisms and to accumulate in normal tissues especially
at kidney and liver. In example, 14 peptides was synthesized, labeled with technetium-99m, and tested for their biodistribution and
use for detecting laryngeal cancer in nude mouse. Also a artificial tumor
antigen, i.e. epitope VTSAPDTRPAPGST of mucin core protein, was synthesized, conjugated to albumin, and used to measure the affinity of

L17 ANSWER 40 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
the peptides.

L17 ANSWER 41 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:155533 CAPLUS
DOCUMENT NUMBER: 124:212160
TITLE: Monoamine, diamide, thiol-containing metal chelating agents
INVENTOR(S): Mcbride, William; Dean, Richard T.
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533497	A1	19951214	WO 1995-US6914	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2191951	AA	19951214	CA 1995-2191951	19950601
AU 9526944	A1	19960104	AU 1995-26944	19950601
AU 707040	B2	19990701		
BR 9507917	A	19970812	BR 1995-7917	19950601
CN 1158090	A	19970827	CN 1995-194356	19950601
CN 1093424	B	20021030		
EP 804252	A2	19971105	EP 1995-922159	19950601
EP 804252	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 10501531	T2	19980210	JP 1995-501181	19950601
AT 246939	E	20030815	AT 1995-922159	19950601
PT 804252	T	20031231	PT 1995-922159	19950601
ES 2204954	T3	20040501	ES 1995-922159	19950601
ZA 9504548	A	19960315	ZA 1995-4548	19950602
PRIORITY APPLN. INFO.:			US 1994-253973 A	19940603
			WO 1995-US6914 W	19950601

OTHER SOURCE(S): MARPAT 124:212160
AB The invention relates to reagents useful in preparing radiolabeled diagnostic and therapeutic agents (radiopharmaceuticals). Specifically, the invention provides such reagents that are monoamine, diamide, and thiol-containing metal chelators. Methods of making such reagents, and methods of using the radiopharmaceuticals produced therefrom are also provided.

L17 ANSWER 42 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:147789 CAPLUS
DOCUMENT NUMBER: 124:197258
TITLE: Technetium-99m-labeled peptides for imaging
INVENTOR(S): Dean, Richard T.; Buttram, Scott; McBride, William; Lister-James, John; Civitello, Edgar R.
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533498	A1	19951214	WO 1995-US7017	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5997844	A	19991207	US 1994-253678	19940603
AU 9527783	A1	19960104	AU 1995-27783	19950601
AU 697048	B2	19980924		
EP 762901	A1	19970319	EP 1995-922946	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10501241	T2	19980203	JP 1996-501223	19950601
PRIORITY APPLN. INFO.:			US 1994-253678 A	19940603
			US 1991-653012 B2	19910208
			US 1993-92355 A2	19930715
			WO 1995-US7017 W	19950601

OTHER SOURCE(S): MARPAT 124:197258
AB Radiolabeled peptides and methods for producing them are disclosed. Specifically, the invention relates to peptides, methods, and kits for making the peptides, as well as methods for using such peptides to image sites in a mammalian body labeled with technetium-99m via a radiolabel-binding moiety covalently attached to a specific binding peptide via an amino acid side-chain of the peptide. Peptide sequences are included.

L17 ANSWER 43 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:142190 CAPLUS
DOCUMENT NUMBER: 124:185700
TITLE: Radiolabeled compounds for thrombus imaging
INVENTOR(S): Dean, Richard T.; Lister, James, John; Civitello, Edgar R.; Mcbride, William
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533496	A1	19951214	WO 1995-US6909	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5830856	A	19981103	US 1994-253317	19940603
AU 9527642	A1	19960104	AU 1995-27642	19950601
AU 709306	B2	19990826		
EP 772460	A1	19970514	EP 1995-940908	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10501236	T2	19980203	JP 1995-501180	19950601
PRIORITY APPLN. INFO.:			US 1994-253317 A	19940603
			US 1991-653012 B2	19910208
			US 1993-44825 B2	19930408
			WO 1995-US6909 W	19950601

OTHER SOURCE(S): MARPAT 124:185700
AB This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compds., including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compds., and methods for using such compds. labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.

L17 ANSWER 44 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:38230 CAPLUS
DOCUMENT NUMBER: 124:169544
TITLE: Technetium-99m-labeled peptides as scintigraphic imaging agents
INVENTOR(S): Dean, Richard T.; Lister-James, John; Mcbride, William
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9529708	A1	19951109	WO 1995-US5340	19950501
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2189420	AA	19951109	CA 1995-2189420	19950501
AU 9524633	A1	19951129	AU 1995-24633	19950501
AU 704460	B2	19990422		
EP 772459	A1	19970514	EP 1995-918875	19950501
EP 772459	B1	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1152881	A	19970625	CN 1995-193737	19950501
CN 1087955	B	20020724		
JP 09512555	T2	19971216	JP 1995-528440	19950501
AT 234639	E	20030415	AT 1995-918875	19950501
PT 772459	T	20030630	PT 1995-918875	19950501
ES 2194908	T3	20031201	ES 1995-918875	19950501
ZA 9503494	A	19960628	ZA 1995-3494	19950502
PRIORITY APPLN. INFO.:			US 1994-236402 A2	19940502
			WO 1995-US5340 W	19950501

OTHER SOURCE(S): MARPAT 124:169544
AB A scintigraphic imaging agent for imaging sites in a mammalian body comprises a specific binding compound of mol. weight <10,000 covalently linked to a radiolabel-complexing peptide R1COA1A2Z [R1 = C1-4 alkyl, covalent linkage to specific binding compound; A1, A2 = amino acid not containing an SH group; Z = SH-containing group selected from Cys, homocysteine, isocysteine, penicillamine, HSCH2CH2NH2, HSCH2CH2CH2NH2; if Z contains a CO group, it is linked to OH, (substituted) amino, amino acid, or (cyclic) peptide] or YA2A1NHR2 [Y = Z above, linked (if any of 1st 4 compds.) to H, amino acid, or (cyclic) peptide; A1, A2 as above; R2 = H, C1-4 alkyl, covalent linkage to specific binding compound]. The radiolabel (e.g. 99mTc)-complexing moiety is covalently linked to the specific binding compound through R1, R2, a sidechain group of A1 or A2, or the NH2 or CO2H group of Cys, homocysteine, isocysteine, or penicillamine. These compds., owing to their low mol. weight, are not likely to be immunogenic and are cleared rapidly from the vasculature, allowing for rapid imaging and diagnosis.

L17 ANSWER 44 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
The reagent may alternatively contain a polyvalent linking moiety covalently linked to multiple specific binding compds. and multiple radiolabel-complexing peptides. Thus, 99mTc-labeled HSCH2CO-GGGRALVDTLKFVTQAEGAK-NH2 was injected into rabbits which had been fed a cholesterol-rich diet for imaging of atherosclerotic plaques with a γ camera.

L17 ANSWER 45 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:995181 CAPLUS
DOCUMENT NUMBER: 124:117980
TITLE: Preparation of O-(piperidylalkyl)tyrosine derivatives as reagents for preparing scintigraphic imaging agents for the diagnosis of thrombosis.
INVENTOR(S): Lister-James, John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9525720	A1	19950928	WO 1995-US3366	19950317
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9521866	A1	19951009	AU 1995-21866	19950317
ZA 9502206	A	19951212	ZA 1995-2206	19950317
EP 750610	A1	19970102	EP 1995-914746	19950317
EP 750610	B1	20011212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, MC, SE				
AT 210644	E	20011215	AT 1995-914746	19950317
ES 2169756	T3	20020716	ES 1995-914746	19950317
PRIORITY APPLN. INFO.:			US 1994-210822 A	19940318
			WO 1995-US3366 W	19950317

OTHER SOURCE(S): MARPAT 124:117980
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Reagents [I, II; L = (CR2)5, (OCR2)4, (CR2)2NHCOCR2, CR2OCR2CONH, etc.; R = H, alkyl, cycloalkyl; RR = alkylidene; W = radiolabel binding moiety having a mol. weight of <500 daltons], capable of binding to platelet glycoprotein IIb/IIIa receptors and capable of inhibiting by 50% ADP-induced aggregation of human platelets in platelet-rich plasma at ≤1.0 μM, were prepared (no data). Claimed compds. include (III) and (IV).

L17 ANSWER 46 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:735479 CAPLUS
DOCUMENT NUMBER: 123:123129
TITLE: Compositions containing heat-stable toxin conjugates that specifically bind to colorectal cancer cells and methods for their use
INVENTOR(S): Waldman, Scott A.
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9511694	A1	19950504	WO 1994-US12232	19941026
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5518888	A	19960521	US 1993-141892	19931026
US 5601990	A	19970211	US 1994-305056	19940913
CA 2174928	AA	19950504	CA 1994-2174928	19941026
AU 9481249	A1	19950522	AU 1994-81249	19941026
AU 681920	B2	19970911		
EP 734264	A1	19961002	EP 1995-900421	19941026
EP 734264	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09506340	T2	19970624	JP 1994-512781	19941026
AT 259648	E	20040315	AT 1995-900421	19941026
NO 9601706	A	19960620	NO 1996-1706	19960426
US 6060037	A	20000509	US 1996-635930	19960426
US 5731159	A	19980324	US 1997-789270	19970128
US 5928873	A	19990727	US 1998-46178	19980323
US 6268159	B1	20010731	US 1998-136237	19980821
US 6455251	B1	20020924	US 1999-304193	19990503
US 2003068641	A1	20030410	US 2002-253321	20020924
PRIORITY APPLN. INFO.:			US 1993-141892 A	19931026
			US 1994-305056 A	19940913
			WO 1994-US12232 W	19941026
			US 1995-468449 A3	19950606
			US 1997-789270 A1	19970128
			US 1998-46178 A1	19980323
			US 1999-304193 A3	19990503

AB Conjugated compds. which comprise an heat-stable toxin (ST) receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compns. comprising conjugated compound which comprises an

L17 ANSWER 46 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. The ST receptor binding moiety can be any of 52 peptide portions of heat-stable toxins (E. coli ST Ia, ST Ib, guanylin, etc.), and the active moiety can be various drugs (methotrexate, etoposide), toxins (ricin A chain, diphtheria toxin), or radionuclides (47Sc, 32P, etc.). Methods of treating an individual suspected of suffering from metastasized colorectal cancer are disclosed. Methods of radioimaging metastasized colorectal cancer cells are disclosed. In vitro methods, kits, and reagents are disclosed for detg. whether or not an individual has metastasized colorectal cancer cells, for detg. whether tumor cells are colorectal in origin, and for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells.

L17 ANSWER 47 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:615003 CAPLUS
DOCUMENT NUMBER: 123:33650
TITLE: Preparation of metal complexes of endothelin analogs and radioiodinated endothelin analogs for diagnosis of cardiovascular disease
INVENTOR(S): Dinkelborg, Ludger; Erber, Sebastian; Hilger, Christoph Stephen; Kramp, Wolfgang; Schier, Hans-Martin; Speck, Ulrich; Gries, Heinz; Platzek, Johannes; Reiser, Joseph H.
PATENT ASSIGNEE(S): Institut fuer Diagnostikforschung GmbH an der Freien Universitaet Berlin, Germany
SOURCE: Ger. Offen., 39 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4301871	A1	19940714	DE 1993-4301871	19930113
EP 606683	A2	19940720	EP 1993-250286	19931022
EP 606683	A3	19951227		
EP 606683	B1	20030102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 230416	E	20030115	AT 1993-250286	19931022
CA 2113245	AA	19940714	CA 1994-2113245	19940111
AU 9453146	A1	19940721	AU 1994-53146	19940112
AU 666059	B2	19960125		
ZA 9400186	A	19940818	ZA 1994-186	19940112
IL 108322	A1	20010520	IL 1994-108322	19940112
JP 07149799	A2	19950613	JP 1994-2268	19940113
JP 3558169	B2	20040825		
PRIORITY APPLN. INFO.:			DE 1993-4301871 A	19930113

AB Complexes of ELKb with metal ions of atomic nos. 21-32, 37-39, 42-51, and 57-83 [E = residue of endothelin, endothelin derivative, endothelin antagonist, etc.; L = bond, Z1RZ2; R = (O-, S-, CO-, NH-, alkylimino-, alkyliminocarbonyl-, NHCO-interrupted) (HO- or epoxy-substituted) alkyl; Z1, Z2 = O, S, CO2, NHCSNH, CO, CSO, etc.; K = chelating residue; b = 0,1], and radioiodoendothelin derivs., were prepared for diagnosis of cardiovascular disease. Thus, S-benzoylthioacetyl-Gly-Gly-Gly-OH and N-hydroxysuccinimide in DMF at -15° were treated with DCC in DMF; the mixture was stirred 2 h at -5°, 2 h at room temp, and then cooled to -15° and filtered. The filtrate was combined with H-Gly-Asp-His-Leu-Asp-Ile-Ile-Trp-OH and the mixture was stirred 20 h at room temperature to give S-benzoylthioacetyl-Gly-Gly-Gly-Gly-Asp-His-Leu-Asp-Ile-Ile-Trp-OH. This was treated with a pertechnate solution in a citrate buffer to give S-benzoylthioacetyl-Gly-Gly-Gly-Gly-Asp-His-Leu-Asp-Ile-Ile-Trp-OH 99m-Tc complex. 123I-labeled endothelin 1 was prepared and used to image

L17 ANSWER 47 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
atherosclerotic changes in rabbit aortas via autoradiog.

L17 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:452298 CAPLUS
DOCUMENT NUMBER: 124:49695
TITLE: Somatostatin derivatives and their radiolabelled products
INVENTOR(S): Mcbride, William; Dean, Richard T.
PATENT ASSIGNEE(S): Diatech, INc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9503330	A1	19950202	WO 1994-US8335	19940721
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5620675	A	19970415	US 1993-95760	19930721
AU 9475506	A1	19950220	AU 1994-75506	19940721
AU 684823	B2	19980108		
JP 09501419	T2	19970210	JP 1995-505359	19940721
JP 3601827	B2	20041215		
EP 804481	A1	19971105	EP 1994-925686	19940721
EP 804481	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, IE				
AT 237637	E	20030515	AT 1994-925686	19940721
US 6241965	B1	20010605	US 1996-586670	19960422
PRIORITY APPLN. INFO.:			US 1993-95760 A	19930721
			US 1992-902935 A2	19920623
			WO 1994-US8335 W	19940721

OTHER SOURCE(S): MARPAT 124:49695
AB Linear peptide derivs. and analogs of somatostatin radiolabeled with 99mTc are useful as scintigraphic imaging agents. Linear peptide derivs. and analogs of somatostatin radiolabeled with cytotoxic radioisotopes such as 186Re and 188Re are useful as radiotherapeutic agents. Methods and kits for making, radiolabeling, and using such peptides diagnostically and therapeutically in a mammal are provided.

L17 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:274998 CAPLUS
DOCUMENT NUMBER: 122:75610
TITLE: Bifunctional chelators and their use in radiopharmaceuticals
INVENTOR(S): Erber, Sebastian; Dinkelborg, Ludger; Rohlfs, Gerhard; Schulze, Paul-Eberhard; Noll, Bernhard
PATENT ASSIGNEE(S): Institut fuer Diagnostikforschung GmbH an der Freien Universitaet Berlin, Germany
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422491	A1	19941013	WO 1994-DE369	19940329
W: AU, CA, HU, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 4311021	A1	19941027	DE 1993-4311021	19930331
CA 2156618	AA	19941013	CA 1994-2156618	19940329
AU 9465015	A1	19941024	AU 1994-65015	19940329
EP 692979	A1	19960124	EP 1994-912439	19940329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 72733	A2	19960528	HU 1995-2858	19940329
JP 08508261	T2	19960903	JP 1994-521540	19940329
NO 9503865	A	19951123	NO 1995-3865	19950929
PRIORITY APPLN. INFO.:			DE 1993-4311021 A	19930331
			WO 1994-DE369 W	19940329

OTHER SOURCE(S): CASREACT 122:75610; MARPAT 122:75610
AB New technetium and rhenium chelate compds. are disclosed, as well as a process for their preparation, radiopharmaceuticals containing these compds., conjugates of these compds. with substances which selectively accumulate in diseased tissues, in particular peptides and proteins, as well as the preparation of compns. containing these compds. and their use in radiodiagnostic examns. Thus, successive condensation of glycylglycylpropargylamide with acetylmercaptosuccinic anhydride followed by hexadecylamine produced N-(3-hexadecylaminocarbonyl-2-acetylthiopropionyl)glycylglycylpropargylamide, which was converted to a 99mTc complex with TcO4-. When injected i.v. into rabbits, this complex became localized in atherosclerotic plaques.

L17 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:293143 CAPLUS
DOCUMENT NUMBER: 120:293143
TITLE: Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9400489	A2	19940106	WO 1993-US6029	19930623
WO 9400489	A3	19940331		
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5716596	A	19980210	US 1992-902935	19920623
AU 9347688	A1	19940124	AU 1993-47688	19930623
AU 690071	B2	19980423		
EP 649434	A1	19950426	EP 1993-918129	19930623
EP 649434	B1	20010801		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 08503924	T2	19960430	JP 1994-502568	19930623
EP 1094074	A2	20010425	EP 2000-122243	19930623
EP 1094074	A3	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
AT 203754	E	20010815	AT 1993-918129	19930623
ES 2164667	T3	20020301	ES 1993-918129	19930623
CA 2138647	C	20021112	CA 1993-2138647	19930623
ZA 9307596	A	19940804	ZA 1993-7596	19931013
AU 9470990	A1	19950117	AU 1994-70990	19940603
AU 701083	B2	19990121		
EP 720621	A1	19960710	EP 1994-920076	19940603
EP 720621	B1	20010207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, SE				
AT 199089	E	20010215	AT 1994-920076	19940603
EP 1092726	A2	20010418	EP 2000-122241	19940603
EP 1092726	A3	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, IE				
EP 1099707	A2	20010516	EP 2000-122242	19940603
EP 1099707	A3	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, IE				
ES 2158897	T3	20010916	ES 1994-920076	19940603
ZA 9404498	A	19960624	ZA 1994-4498	19940623
US 5871711	A	19990216	US 1995-347397	19950113
US 5814298	A	19980929	US 1995-465764	19950606
US 5820845	A	19981013	US 1995-466100	19950606
US 5833942	A	19981110	US 1995-470932	19950606
US 5843401	A	19981201	US 1995-467025	19950606
AU 9877481	A1	19981001	AU 1998-77481	19980723
AU 776961	B2	20040930	AU 2001-18288	20010205
AU 2001018288	A5	20011213		

L17 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GR 3035830	T3	20010831	GR 2001-400678	20010507
PRIORITY APPLN. INFO.:			US 1992-902935	A2 19920623
			EP 1993-918129	A3 19930623
			WO 1993-US6029	A 19930623
			US 1993-92355	A 19930715
			EP 1994-920076	A 19940603
			WO 1994-US6274	W 19940603
			AU 1998-77481	A3 19980723

OTHER SOURCE(S): MARPAT 120:293143
AB Peptide derivs. and analogs of somatostatin, and embodiments of such peptides labeled with 99mTc, 186Re, or 188Re are presented, as well as methods and kits for making, radiolabeling and using such peptides for imaging or therapy in a mammalian body. CH2CO-FFWDKTFCCAcmGCAcmamide (I) was prepared by solid phase peptide synthesis and radiolabeled with 99mTc.
I inhibited binding of [125I-Tyr11]somatostatin-14 to AR42J rat pancreatic
tumor cell membrane somatostatin receptors with a Ki = 0.16 nM.

L17 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:239252 CAPLUS
DOCUMENT NUMBER: 120:239252
TITLE: Technetium-99m labeled peptides for imaging
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325244	A1	19931223	WO 1993-US5372	19930604
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5508020	A	19960416	US 1992-893981	19920605
AU 9345287	A1	19940104	AU 1993-45287	19930604
AU 688264	B2	19980312		
EP 644778	A1	19950329	EP 1993-915221	19930604
EP 644778	B1	19970514		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 07506592	T2	19950720	JP 1994-501622	19930604
JP 2954354	B2	19990927		
AT 152918	E	19970515	AT 1993-915221	19930604
ES 2105292	T3	19971016	ES 1993-915221	19930604
CA 2137009	C	20011127	CA 1993-2137009	19930604
US 5951964	A	19990914	US 1995-341537	19950126
US 5976494	A	19991102	US 1995-469858	19950606
US 6113878	A	20000905	US 1995-467567	19950606
US 6667389	B1	20031223	US 1997-889212	19970708
US 5997845	A	19991207	US 1997-902367	19970729

L17 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PRIORITY APPLN. INFO.:	US 1992-893981	A2	19920605
	US 1991-653012	B2	19910208
	US 1992-886752	B1	19920521
	US 1993-44825	B1	19930408
	WO 1993-US5372	A	19930604
	US 1994-273274	A2	19940711
	US 1994-319997	B1	19941007
	US 1995-439905	A3	19950512
	US 1995-462668	B1	19950605
	US 1995-469858	A	19950606

OTHER SOURCE(S): MARPAT 120:239252
AB Radiolabeled reagents, especially peptides with specific binding properties, and
their preparation for use as scintigraphic imaging agents are described. Reagents, methods and kits for making labeled peptides, and methods for using them labeled with technetium-99m (Tc-99m) via Tc-99m binding moieties comprising said reagents, are described. In particular, the specific-binding peptides and Tc-99m binding moieties of these reagents are covalently linked to a polyvalent linker that is covalently linked to several of the specific-binding peptides, and the Tc-99m binding
moieties are covalently linked to several of the specific-binding peptides, the polyvalent linker moiety, or to both the specific-binding peptides and the polyvalent linker moiety. The Tc chelating moiety BAT-EM
(N-[N',N'-bis(2-maleimidoethyl)aminoethyl)]-N6,N9-bis(2-methyl-2-triphenylmethylthiopropyl)-6,9-diazanonanamide was prepd. by the reaction of N9-(t-butoxycarbonyl)-N6,N9-bis(2-methyl-2-triphenylmethylthiopropyl)-6,9-diazanonanoic acid with N-hydroxy succinimide and tris-(2-aminoethyl)amine. The polyvalent linking moiety TMEA, tris(2-maleimidoethyl)amine, was synthesized by the reaction of tris(2-aminoethyl)amine and N-carbomethoxymaleimide. Peptides for the reagents were prepd. by Fmoc chem. and conjugated with the linking moiety and the chelating moieties through reactive groups on the peptide. The use of one such peptide in the imaging of deep vein thrombosis of dogs is demonstrated.

L17 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:239251 CAPLUS
DOCUMENT NUMBER: 120:239251
TITLE: **Technetium-99m-labeled peptides for thrombus imaging**
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323085	A1	19931125	WO 1993-US4794	19930521
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9343845	A1	19931213	AU 1993-43845	19930521
AU 677208	B2	19970417		
EP 641222	A1	19950308	EP 1993-914023	19930521
EP 641222	B1	20000906		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 07508289	T2	19950914	JP 1994-503844	19930521
JP 2941057	B2	19990825		
EP 1004322	A2	20000531	EP 1999-124003	19930521
EP 1004322	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
AT 196094	E	20000915	AT 1993-914023	19930521
ES 2150945	T3	20001216	ES 1993-914023	19930521
CA 2136330	C	20020319	CA 1993-2136330	19930521
ZA 9307543	A	19940805	ZA 1993-7543	19931012
US 5925331	A	19990720	US 1995-335832	19950105
US 5997845	A	19991207	US 1997-902367	19970729
JP 10291939	A2	19981104	JP 1998-45661	19980226
JP 3380738	B2	20030224		

PRIORITY APPLN. INFO.:		
US 1992-886752	A2	19920521
US 1991-653012	B2	19910208
US 1992-893981	A3	19920605
US 1993-44825	B1	19930408
EP 1993-914023	A3	19930521
JP 1994-503844	A3	19930521
WO 1993-US4794	A	19930521
US 1994-273274	A2	19940711
US 1995-439905	A3	19950512
US 1995-462668	B1	19950605

L17 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 1995-469858 A 19950606

OTHER SOURCE(S): MARPAT 120:239251
AB Radiolabeled reagents that are scintigraphic imaging agents for imaging sites of thrombus formation in vivo, and methods for producing such reagents, are disclosed. Specifically, the reagents comprise a specific binding compound, capable of binding to ≥1 component of a thrombus, covalently linked to a 99mTc-binding moiety. The invention provides these reagents, methods and kits for making such reagents, and methods for using such reagents labeled with technetium-99m to image thrombus sites in a mammalian body. Deep vein thrombosis in a canine model was imaged using (CH2CO-D-Y-Apc-GDCGGCAcmGCAcmGGC-amide)2-[BAT-BS] radiolabeled with 99mTc {I; Apc = L-S-(3-aminopropyl)Cys; Acm = acetamidomethyl; BAT-BS = N-[2-N,N-bis(2-succinimidoethyl)aminoethyl]-N6,N9-bis(2-mercapto-2-methylpropyl)-6,9-diazanonanamide}. I inhibited the aggregation of human platelets in platelet-rich plasma with an IC50 of 0.081 μM. Preparation of radiolabeled peptides is described.

L17 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:157686 CAPLUS
DOCUMENT NUMBER: 120:157686
TITLE: **Technetium-99m labeled peptides for imaging**
INVENTOR(S): Dean, Richard T.; Buttram, Scott; Mcbride, William; Lister-James, John; Civitello, Edgar R.
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9321962	A1	19931111	WO 1993-US3687	19930419
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5965107	A	19991012	US 1992-871282	19920430
AU 9341076	A1	19931129	AU 1993-41076	19930419
AU 681080	B2	19970821		
EP 637968	A1	19950215	EP 1993-910660	19930419
EP 637968	B1	19990908		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
JP 07506111	T2	19950706	JP 1993-519337	19930419
CA 2111863	C	20010424	CA 1993-2111863	19930419
US 6086849	A	20000711	US 1995-170299	19950209

PRIORITY APPLN. INFO.:		
US 1992-871282	A2	19920430
US 1992-851074	B2	19920313
WO 1993-US3687	A	19930419

OTHER SOURCE(S): MARPAT 120:157686
AB Radiolabeled peptides, and methods for producing such peptides, are disclosed. Specifically, the invention relates to peptides, methods, and kits for making such peptides, and methods for using such peptides to image sites in a mammalian body. The peptides are labeled with technetium-99m (Tc-99m) via a radiolabel-binding moiety which forms a neutral complex with Tc-99m. Preparation of chelators and labeled peptides is described, as is imaging of atherosclerotic plaques and of deep vein thrombosis using the peptides.

L17 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:49086 CAPLUS
DOCUMENT NUMBER: 120:49086
TITLE: **Method using gamma-emitting radionuclide-labeled peptide compound for intraoperatively detecting and locating tumor tissues, and therapeutic use**
INVENTOR(S): Ensing, Geert Jacob; Panek, Karel Jan; Doedens, Bareld Jan
PATENT ASSIGNEE(S): Mallinckrodt Medical, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318797	A1	19930930	WO 1993-US2772	19930324
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9339675	A1	19931021	AU 1993-39675	19930324
EP 636032	A1	19950201	EP 1993-909165	19930324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
JP 07505621	T2	19950622	JP 1993-516829	19930324

PRIORITY APPLN. INFO.:		
EP 1992-200848	A	19920325
WO 1993-US2772	A	19930324

OTHER SOURCE(S): MARPAT 120:49086
AB A method of intraoperatively detecting an locating tumor tissues in the body of a warm-blooded living being comprises (1) parenterally administering a composition of a peptide compound (Markush included) labeled with a low-energy γ photon-emitting radionuclide, in a quantity sufficient for detection by a γ-detecting probe; (2) after the active substance is taken up by the tumor tissue and after blood clearance of radioactivity, using a radioimmunodetection technique in the relevant area of the body, using a γ-detecting probe. The peptide may have neurokinin-1 receptor affinity or somatostatin receptor affinity or may be a cytokine, growth factor or hormone or derivative or analog thereof. A method of radioguided surgery is also disclosed. Combined use of the prepns. of the invention for detection and therapy is described. Preparation of a DTPA-octreotide kit and labeling of the DTPA-octreotide with e.g. Tb-161 is described.

L17 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:49085 CAPLUS
DOCUMENT NUMBER: 120:49085
TITLE: Technetium-99m labeled peptides for imaging inflammation
INVENTOR(S): Dean, Richard T.; Lees, Robert S.; Buttram, Scott; Lister-James, John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9317719	A1	19930916	WO 1993-US2320	19930312
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9340438	A1	19931005	AU 1993-40438	19930312
AU 683015	B2	19971030		
EP 630265	A1	19941228	EP 1993-911556	19930312
EP 630265	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07504902	T2	19950601	JP 1993-516041	19930312
CA 2131816	C	20010828	CA 1993-2131816	19930312
AT 237365	E	20030515	AT 1993-911556	19930312
PT 630265	T	20030731	PT 1993-911556	19930312
ES 2194846	T3	20031201	ES 1993-911556	19930312
US 6017510	A	20000125	US 1994-266178	19940627
US 5989519	A	19991123	US 1994-290853	19941011
US 5711931	A	19980127	US 1995-472535	19950607
US 5807538	A	19980915	US 1995-484774	19950607
PRIORITY APPLN. INFO.:			US 1992-851074 A2	19920313
			WO 1993-US2320 A	19930312
			US 1994-253678 A2	19940603
			US 1994-266178 A3	19940627

OTHER SOURCE(S): MARPAT 120:49085
AB Scintig. agents for imaging inflammation sites comprise a peptide covalently bound to 99mTc. The peptides are, e.g., Cp(aa)Cp (Cp = protected cysteine; aa = amino acid) or ACZB(CR1R2)nX (A = H, CO2H, CONH2, R4, peptidyl NHOC, CO2 peptidyl; B, X = H, SH, NHR3, NR3 peptidyl, R4; Z = H, R4; R1-4 = H, alkyl; n = 0, 1, 2). The peptides bind specifically to leukocytes, preferably neutrophils. The peptides were prepared by solid-phase synthesis, as usual.

L17 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:425552 CAPLUS
DOCUMENT NUMBER: 115:25552
TITLE: Radiolabeled synthetic peptides for use in thrombus detection
INVENTOR(S): Stuttle, Alan William John
PATENT ASSIGNEE(S): Antisoma Ltd., UK
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9015818	A1	19901227	WO 1990-GB933	19900618
W: GB, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
EP 429626	A1	19910605	EP 1990-909765	19900618
EP 429626	B1	19960424		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04505330	T2	19920917	JP 1990-509749	19900618
AT 137245	E	19960515	AT 1990-909765	19900618
ES 2087155	T3	19960716	ES 1990-909765	19900618
JP 10259195	A2	19980929	JP 1997-277888	19900618
GB 2241243	A1	19910828	GB 1991-3416	19910219
GB 2241243	B2	19930127		
US 5843402	A	19981201	US 1997-816922	19970312
PRIORITY APPLN. INFO.:			GB 1989-14020 A	19890619
			JP 1990-509749 A3	19900618
			WO 1990-GB933 W	19900618
			US 1991-659343 B1	19910321
			US 1992-963127 B1	19921019

AB Radiolabeled peptides (3-10 amino acid units) containing the sequence Arg-Gly-Asp, such as Arg-Gly-Asp-Ser-Tyr (I) or Arg-Gly-Asp-Phe-Tyr, are thrombus, tumor, and cell-adhesion-mol. markers, usable for in vivo diagnosis. I.v. administration of I-123I (preparation given) to rabbits with exptl. thrombosis showed rapid radioactivity uptake by the thrombus.

L17 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:400778 CAPLUS
DOCUMENT NUMBER: 115:778
TITLE: Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
INVENTOR(S): Anderson, David C.; Morgan, A. Charles; Abrams, Paul G.; Nichols, Everett J.; Fritzberg, Alan R.
PATENT ASSIGNEE(S): NeoRx Corp., USA
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 359347	A2	19900321	EP 1989-250014	19890814
EP 359347	A3	19900418		
EP 359347	B1	19921223		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5135736	A	19920804	US 1988-232337	19880815
US 5169933	A	19921208	US 1989-390241	19890807
CA 1334513	A1	19950221	CA 1989-608198	19890811
JP 02124833	A2	19900514	JP 1989-209992	19890814
AT 83669	E	19930115	AT 1989-250014	19890814
PRIORITY APPLN. INFO.:			US 1988-232337 A	19880815
			EP 1989-250014 A	19890814

AB Covalently-linked complexes (CLCs) for targeting a defined population of cells comprise a targeting protein (e.g. antibody, hormone, enzyme, etc.), a cytotoxic agent (e.g. radionuclide, toxin, drug, etc.) an enhancing moiety capable of enhancing CLC-target cell interaction (e.g. a translocating/internalizing moiety, an anchoring peptide, membrane-soluble hydrophobic mol., etc.). The CLCs are used to enhance in vivo cytotoxicity and imaging (no data). Translocating peptide, Cys-Gly-Glu-Ala-Ala-Leu-Ala(Glu-Ala-Leu-Ala)4-Glu-Ala-Leu-Glu-Ala-Leu-Ala-Ala-NH2, is conjugated via succinimidyl 4(N-maleimidemethyl)cyclohexane-1-carboxylate (SMCC) to reduced toxin A chain. The conjugate is reacted with iminothiolane to generate further thiol groups which are then bonded to reduced antibody to prepare translocating peptide-ricin A chain-antibody CLC.

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   176.97     441.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -41.61     -41.61

FILE 'REGISTRY' ENTERED AT 11:11:28 ON 24 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUN 2005  HIGHEST RN 852898-09-0
DICTIONARY FILE UPDATES:  23 JUN 2005  HIGHEST RN 852898-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> dis his

     (FILE 'HOME' ENTERED AT 11:04:10 ON 24 JUN 2005)

     FILE 'REGISTRY' ENTERED AT 11:04:19 ON 24 JUN 2005
L1             STR
L2             STR L1
L3          50 S L1 OR L2
L4       27919 S L1 OR L2 FUL

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 11:08:10 ON 24 JUN 2005

     FILE 'CAPLUS' ENTERED AT 11:08:17 ON 24 JUN 2005
L5          9232 S L4
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

```
                S L5 AND (RHENIUM OR NSC 600662 OR RE/MF OR  7440-15-5/REG# OR

     FILE 'REGISTRY' ENTERED AT 11:09:30 ON 24 JUN 2005
L6             1 S 7440-26-8/RN

     FILE 'CAPLUS' ENTERED AT 11:09:30 ON 24 JUN 2005
L7          3930 S L6

     FILE 'REGISTRY' ENTERED AT 11:09:31 ON 24 JUN 2005
L8           130 S TC/MF

     FILE 'CAPLUS' ENTERED AT 11:09:31 ON 24 JUN 2005
L9         14192 S L8

     FILE 'REGISTRY' ENTERED AT 11:09:32 ON 24 JUN 2005
L10            1 S 7440-15-5/RN

     FILE 'CAPLUS' ENTERED AT 11:09:32 ON 24 JUN 2005
L11        17078 S L10

     FILE 'REGISTRY' ENTERED AT 11:09:33 ON 24 JUN 2005
L12          190 S RE/MF

     FILE 'CAPLUS' ENTERED AT 11:09:33 ON 24 JUN 2005
L13        19984 S L12
L14          145 S L5 AND (RHENIUM OR NSC 600662 OR L13 OR L11 OR TECHNETIUM OR
L15           58 S L14  RAN=(,2000)
L16         6389 S SHARMA S?/AU
L17           57 S L15 NOT L16

     FILE 'REGISTRY' ENTERED AT 11:11:28 ON 24 JUN 2005

=> save l4 russel718/a
```

ANSWER SET L4 HAS BEEN SAVED AS 'RUSSEL718/A'

=> d l4 que stat
L1 STR





VAR G1=33/34
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L2 STR





VAR G1=33/34
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L4 27919 SEA FILE=REGISTRY SSS FUL L1 OR L2

100.0% PROCESSED 138317 ITERATIONS 27919 ANSWERS
SEARCH TIME: 00.00.02

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	441.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-41.61

STN INTERNATIONAL LOGOFF AT 11:11:53 ON 24 JUN 2005

This Page Blank (uspto)